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ABSTRACT 
Obesity is a symptom of metabolic syndrome, a condition that increases lifetime risk of type 2 
diabetes and cardiovascular disease. Proper maintenance of the insulin producing β-cells are 
necessary for glucose homeostasis. Although glucose is the most important nutrient factor 
involved in insulin secretion, we are increasingly becoming aware of the role of trace elements 
such as selenium (Se) in β-cell function. Previously, we reported that the putative Se recycling 
enzyme selenocysteine lyase (Scly) may be involved in regulating lipid and carbohydrate 
metabolism. Scly-/- mice develop a remarkable increase in fasting hyperinsulinemia, warranting 
further investigation into the role of Scly in β-cells. Moreover, we described possible sex 
differences in Scly regulation of energy metabolism. The experiments in the first aim focused on 
the role of Scly in pancreatic islet function. Immunofluorescent imaging studies were employed 
to confirm Scly expression in the pancreatic islet. Glucose-stimulated insulin secretion was 
increased in the absence of Scly-/- in the β-cell-like MIN6 cells but slightly impaired in isolated 
pancreatic islets, indicating Scly may influence islet paracrine signaling. Neither islet 
selenoprotein expression nor sulfur pathway enzyme gene expression were altered when Scly 
is deleted. While Scly is expressed in the islet and its deletion in vivo results in 
hyperinsulinemia, further studies are necessary to determine the mechanistic role of Scly in islet 
function. The second aim built upon previous observations that the role of Scly in energy 
metabolism may be sex-specific. Female Scly-/- mice were found to exhibit increased body fat 
composition when compared to their WT counterparts, but they were protected from 
impairments in insulin signaling. Castration was not sufficient to rescue adiposity or energy 
expenditure, but restored fasting insulin to WT levels in the male Scly-/- mice. Interestingly, 
reduced hypothalamic selenoprotein expression in male and female Scly-/- mice suggest Scly 
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may regulate lipid metabolism indirectly through maintaining hypothalamic function, indicating a 
novel role for Scly as a key regulator in the brain-fat axis.  
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 CHAPTER 1. INTRODUCTION 
1.1 Background 
 Estimated to affect over 30% of the population of the United States alone, obesity is a 
growing world-wide epidemic. Although genetic predisposition has been found to be a 
contributing factor in a small percentage of the obese population1, the current obesity epidemic 
can be attributed to a high caloric diet combined with physical inactivity. Obesity is one of the 
early stages of metabolic syndrome (MetS), a cluster of symptoms which significantly increase a 
person’s risk of developing type 2 diabetes (T2D) and/or cardiovascular disease. In traditional 
views, the path to T2D begins with insulin resistance as a direct result of obesity. To combat 
insulin resistance, the β-cells of the pancreatic islets ramp up insulin production and secretion, 
leading to hyperinsulinemia. In most individuals, this compensatory mechanism by the β-cells is 
sufficient to delay the onset of T2D2. However, a fraction of individuals will eventually 
experience β-cell failure, leading to insulin deficiency and subsequently, hyperglycemia. 
Hyperglycemia is a collective result of diminished glucose uptake by insulin-sensitive tissues 
and the increase in hepatic gluconeogenesis, which is normally inhibited by the presence of 
insulin. Oxidative stress3, endoplasmic reticulum (ER) stress4, inflammation5, glucotoxicity6, and 
lipotoxicity7 have all been found to play causative roles in the path to β-cell dysfunction. 
 Although hyperinsulinemia is a hallmark of T2D, its role in T2D development has largely 
been ignored as it was largely thought that insulin resistance is the chief driver of T2D 
pathophysiology. However, there is growing evidence that hyperinsulinemia can cause and/or 
exacerbate insulin resistance, contributing to a snowball effect during the insulin compensatory 
phase. For instance, transgenic mice containing extra copies of the human insulin gene develop 
insulin resistance8. Moreover in vitro studies have found that insulin directly causes insulin 
resistance as acute insulin exposure induced insulin resistance in dorsal root ganglion neurons9. 
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Thus, a more comprehensive understanding of islet physiology will allow us to find new 
molecular targets to treat T2D. 
1.2 Pancreatic Islet Physiology and Insulin Secretion 
 The pancreatic islet is a structure within the pancreas, which regulates glucose 
homeostasis. Several specialized cell types make up the islet, each producing and secreting a 
different set of hormones. The β-cell constitutes 60-80% of the islet, and is the main site of 
insulin production. Insulin stimulates glucose uptake in insulin-sensitive tissues as well as 
inhibiting gluconeogenesis, thereby reducing blood glucose levels. Working in opposition to 
insulin is glucagon, which is produced and secreted by the α-cell10. Glucagon is released when 
blood glucose levels fall below a certain threshold11 and raises blood glucose levels via 
stimulation of hepatic gluconeogenesis12. Other cell types within the islet include the δ-cells that 
secrete somatostatin13, ε-cells that secrete ghrelin14, and PP-cells that secrete pancreatic 
polypeptide. These pancreatic hormones work in tandem to fine tune blood glucose levels. 
 Of the different cell types that make up the islet, the β-cell is perhaps the most well-
studied, due to insulin being the first of the pancreatic hormones to be discovered. The classical 
insulin secretory pathway is known as glucose stimulated insulin secretion (GSIS), and the 
process begins with glucose entry into the β-cell via glucose transporters (GLUT2 in rodents 
and GLUT1 and 3 in humans). As glucose undergoes glycolysis to form pyruvate, ~50% of the 
pyruvate formed is oxidized to acetyl-CoA by pyruvate dehydrogenase (PDH) to produce NADH 
and FADH2, which can be oxidized through the respiratory transport chain. As a result, 
intracellular adenosine tri-phosphate (ATP) can be synthesized through oxidative 
phosphorylation, and the rise in ATP/ADP closes ATP-sensitive K+ channels (KATP)15. This 
results in membrane depolarization, stimulating influx of Ca2+ through voltage-dependent L-type 
Ca2+ channels. The increase in intracellular Ca2+ concentration subsequently triggers exocytosis 
3 
 
of insulin granules16. In a parallel pathway, pyruvate is carboxylated by pyruvate carboxylase 
(Pcx) to participate in anaplerosis, through which additional second messengers and reducing 
equivalents required for insulin secretion are generated17. 
 In terms of protection from oxidative stress, the pancreatic islet is a unique environment 
as levels of antioxidant enzymes are kept at minimal levels. During glucose metabolism, the 
formation of NADH and FADH2 stimulates superoxide anion production. Superoxide dismutase 
(SOD) converts superoxide anion to H2O2, which is quickly inactivated by H2O2 scavenging 
enzymes18. SOD activity in islets is less than 50% of that observed in the liver, and less than 
10% of the activity levels of H2O2 scavenging enzymes, catalase and glutathione peroxidase 
(GPX)19. Interestingly, glucose stimulation was found to transiently increase intracellular reactive 
oxygen species (ROS) levels in the β-cell20, leading to the hypothesis that ROS may be an 
important signal in insulin secretion. Strikingly, not only was mitochondrial ROS found to 
increase insulin secretion, the glucose-induced rise in mitochondrial ROS was found to be 
essential for insulin secretion21. Thus, the reason for tight regulation of antioxidant activity in the 
β-cell is likely to create a condition that is sensitive to slight changes in ROS. While reduced 
antioxidant expression in β-cells is advantageous for ROS signaling, it acts as a double-edged 
sword19, potentially leaving β-cells more vulnerable to oxidative damage.  
 Other nutrient signals such as fatty acids22 and amino acids23, can also stimulate insulin 
release. In addition, gastrointestinal peptides such as glucagon-like peptide 1 (GLP-1) and the 
autonomic nervous system can potentiate insulin secretion. Understanding the mechanism of 
action of these additional insulinotropic agents is paramount to developing drugs to treat β-cell 
dysfunction. Moreover, while the contributions of macronutrients such as glucose or fats to 
metabolic diseases are well-studied, the influence of micronutrients such as Se is unclear.  
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1.3 Selenium 
 Dietary Selenium (Se) is critical for the synthesis of selenoproteins, which carry out the 
biological functions of Se. To date, 24 murine and 25 human selenoprotein genes have been 
identified24. Of these gene products, the glutathione peroxidases and thioredoxin reductases, 
which participate in redox reactions, are likely the most well-studied selenoprotein families. 
Other notable selenoproteins with known functions include the iodothyronine deiodinase family, 
which regulate thyroid hormone activation and Selenoprotein P (SELENOP), which transports 
Se through the serum. Thus, selenoproteins function in a wide variety of cellular processes 
(Table 1). 
 Selenoprotein synthesis involves several processes that are distinct from normal protein 
translation. Eukaryotic selenocysteine (Sec) biosynthesis is a unique process beginning with the 
synthesis of Sec directly on its tRNA (Sec-tRNA[Ser]Sec)25. Perhaps one the most intriguing 
aspects of selenoprotein biosynthesis is the ability of Sec-tRNA[Sec]Ser to recognize the UGA 
codon, allowing for the recoding of what is conventionally a stop codon into a Sec insertion site. 
Consequently, intricate mechanisms have evolved to prevent premature translation termination. 
One of these is the unique secondary structure known as the Sec Insertion Sequence (SECIS) 
element in the 3’ untranslated region of the selenoprotein mRNA26 which recruits several trans-
acting elements that are necessary for selenoprotein translation.   
 The presence of Se regulates selenoprotein synthesis. It was recently demonstrated 
through ribosome profiling that Se influence over selenoprotein synthesis occurs mainly through 
changes in translational efficiency27. Reduced Sec incorporation causes the UGA codon to be 
read as a premature stop codon, activating the nonsense-mediated decay (NMD) pathway28. 
Nevertheless, it is important to note that selenoproteins are not affected equally by this pathway.  
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Table 1. List of selenoproteins and their known functions. 
  
Selenoprotein Gene Abbreviation Function(s) 
15 kDa-selenoprotein SELENOF Protein folding 
Iodothironine Deiodinase 1–3 DIO1–3 Thyroid hormone activity regulation 
Glutathione Peroxidase 1–4, 6 GPX1–6 
Hydroperoxide/phospholipid 
peroxide reduction 
Methionine-R-Sulfoxide 
Reductase 1 
MSRB1 
Reduces oxidized methionine 
residues 
Selenoprotein H SELENOH Genome maintenance 
Selenoprotein I SELENOI Unknown 
Selenoprotein K SELENOK 
ER-associated degradation; 
inflammation 
 
Selenoprotein M SELENOM Ca2+ homeostasis 
Selenoprotein N SELENON Muscle development 
Selenoprotein O SELENOO Unknown 
Selenoprotein P SELENOP Selenium transport 
Selenoprotein S SELENOS 
ER-associated degradation; 
inflammation 
 
Selenophosphate Synthetase 2 SEPHS2 Selenoprotein biosynthesis 
Selenoprotein T SELENOT 
Ca2+ homeostasis; neuroendocrine 
secretion 
Thioredoxin Reducase 1–3 TXNRD1–3 Disulfide bond reduction 
Selenoprotein V SELENOV Unknown 
Selenoprotein W SELEONOW Redox reaction 
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Housekeeping selenoproteins such as TXNRD1 and glutathione peroxidase 4 (GPX4) are more 
resistant to changes in Se levels and are essential for life, as evidenced by the fact that whole- 
body knockout of these selenoproteins is embryonic lethal29,30. On the other hand, “stress-
response” selenoproteins are more reactive to fluctuating Se status and, while crucial for the 
molecular mechanisms they are involved in, are not considered to be essential to life. 
1.4 Selenocysteine Lyase and Se Metabolism 
 Sec decomposition occurs through selenocysteine lyase (Scly), a pyridoxal 5'-
phosphate-dependent enzyme that was initially purified from pig liver31. Scly has the ability to 
specifically distinguish Sec from the structurally similar amino acid, cysteine (Cys)32. In the 
presence of cofactor pyridoxal 5-phosphate, Scly cleaves Sec to form alanine and selenide. The 
released selenide can be further metabolized and excreted or it can be re-purposed for 
selenoprotein synthesis, implicating a role for Scly as a Se recycling enzyme when Se supply is 
low (Figure 1). In vitro immunoprecipitation studies demonstrated Scly interaction with 
selenophosphate synthetase 1 (SPS1) and SPS2, suggesting that these enzymes work in a 
complex where Sec donates Se to SPS to form selenophosphate33. Moreover, Scly and 
Biosynthesis 
Selenoproteins undergo proteolysis to release Sec. Scly further metabolizes Sec to produce 
selenide and alanine (Ala). Through a potential interaction with SPS, Scly possibly salvages 
Se to be repurposed in selenoprotein biosynthesis. 
Figure 1. Schematic representation of Scly in Sec degradation and Se recycling. 
7 
 
SELENOP have been suggested to act in tandem, with SELENOP delivering Sec to tissues 
where Scly can cleave and recycle Se34. In support of this, mice lacking both Scly and 
SELENOP develop severe neurological deficits, surpassing the neurological phenotypes 
observed when only one gene is absent35.  
 Unlike classical amino acids, free Sec is kept at minimal levels, likely because its high 
reactivity is capable of producing harmful free radicals. Moreover, there is a possibility that Sec 
can compete with Cys and become misincorporated into proteins, resulting in misfolded 
proteins36. Strikingly, a study involving transgenic expression of Scly in Arabidopsis plants 
highlighted a role for Scly in mitigating Sec toxicity through its degradation37. Yet, we found that 
Scly deletion in mice does not appear to generate symptoms indicative of severe toxicity due to 
Sec accumulation38. Therefore, an alternate pathway that is capable of decomposing Sec must 
exist. One candidate pathway is the consumption of Sec through sulfur metabolism. Several 
studies have confirmed that Se and its derivatives can be metabolized via sulfur pathways, 
albeit many of these studies were conducted in plants and must be verified in vertebrates39. 
1.5 Physiological Role of Selenocysteine Lyase 
 Until recently, much of the work on Scly utilized in vitro methods31, and so the 
physiological role Scly has remained elusive. We generated Scly knockout (Scly-/-) mice, 
uncovering a potential relationship for Scly in regulating energy metabolism.  The Scly-/- mice 
develop a metabolic syndrome-like phenotype under a Se adequate diet, displaying 
hyperinsulinemia, increased body weight, dyslipidemia, and reduced glucose tolerance38; 
however, a mechanistic link has yet to be determined. Under Se adequate conditions, hepatic 
selenoprotein levels are unchanged38, suggesting that Scly regulation of glucose metabolism 
may be independent from its known function in selenoprotein biosynthesis.  
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 On the other hand, under Se deficient conditions, the metabolic phenotype of Scly-/- mice 
is exacerbated38. Additionally, hepatic expression of GPX1 and SELENOS, and serum 
SELENOP levels were diminished, strengthening the hypothesis that Scly-/- is important in Se 
recycling when Se supply is low. Thus, it appears that Scly directly regulates selenoprotein 
expression in Se deficiency, and reduced selenoprotein expression contributes to altered 
energy metabolism in Scly-/- mice.  
 High fat diet studies demonstrated that Scly-/- mice are more susceptible to diet-induced 
obesity than their wild-type (WT) counterparts as gluconeogenic and lipogenic enzymes were 
upregulated in Scly-/- mice 40. Altogether, this study suggests Scly may serve as a regulatory 
point connecting energy metabolism with Se pathways. Strengthening the idea that Scly is 
involved in lipid metabolism, a recent genome wide association study involving Mexican-
Americans revealed an intronic variant rs201606363, located between Scly and its conjoined 
gene, ubiquitin-conjugating enzyme E2F (UBE2F)41, to be positively associated with low density 
lipoprotein (LDL), apolipoprotein B (ApoB), and total cholesterol levels. Further studies are 
necessary to determine the mechanistic relationship between cholesterol and Scly. 
1.6 Selenium and T2D: Clinical Trials 
 Se was long touted for its cytoprotective properties, due to its ability to upregulate 
antioxidant selenoenzymes. Thus, it was believed that Se supplementation could prevent the 
onset of metabolic diseases, such as T2D by counteracting oxidative stress. Indeed, Se in the 
form of selenate, was found to act as an insulin mimetic, displaying anti-diabetic effects42. In 
support of this, two cross-sectional studies reported lower baseline Se levels to be associated 
with T2D incidence among elderly French men43, as well as in samples taken from a population 
in southeastern Spain44. A more recent, longitudinal study conducted in the United States, 
reported higher toenail Se to be associated with lower T2D risk45. However, other cross-
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sectional studies, namely the National Health and Nutrition Examination Survey (NHANES) III46 
and NHANES 2003–200447, revealed an association between high Se intake and an increased 
risk for metabolic diseases. Moreover, increased T2D risk was found to be a secondary 
outcome in the Nutritional Prevention of Cancer (NPC) trial, a randomized, controlled trial 
assessing the efficacy of Se supplementation in the form of Se yeast (200 µg/day) in preventing 
skin cancer48. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), testing the 
effects of selenomethionine (SeMet, 200 µg/day) and/or Vitamin E in preventing prostate cancer 
was curtailed as it became apparent Se supplementation was not beneficial in the prevention of 
prostate cancer, and a nonsignificant trend towards T2D in the experimental group was 
reported49,50. Yet, other epidemiological studies and clinical trials failed to find a correlation 
between increased Se and T2D susceptibility51. One reason for the discrepancies in the human 
trials may be due to differences in baseline Se levels. For instance, the mean baseline serum 
Se levels in SELECT49 subjects were already high (136 µg/L) whereas only the NPC51 subjects 
in the upper third tertile of baseline Se (>122 µg/L) demonstrated higher incidence of T2D. 
Strengthening the idea of a narrow beneficial window of Se dose, it is likely that with regards to 
T2D, Se supplementation may be advantageous in populations with low Se status, but 
detrimental in Se-replete populations. In fact, randomized, controlled trials of Se 
supplementation in elderly patients52 and pregnant women53 from the UK, who have lower 
baseline Se than US subjects, did not result in increased T2D risk, as determined by serum 
adiponectin concentration. Another source of the inconsistencies might be attributable to 
differences in Se source, as different Se forms vary in their bioavailability and biological effects. 
Thus, it is difficult to delineate a clear-cut relationship between Se status and T2D based on 
evidence from the current human clinical trials and epidemiological studies. 
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1.7 Selenium and T2D: Animal Models 
 Although the association between Se supplementation and T2D in humans is considered 
controversial, studies in animal models may provide physiological and molecular insights into 
some of the inconsistencies reported in human clinical trials. In a study comparing three 
different concentrations of Se in the diet, it was found that mice on a relatively high 0.4 ppm 
selenite diet developed insulin resistance, a hallmark of T2D54. This concentration of Se is 
comparable to the 200 µg Se regimen that was administered to humans in the NPC trial. High 
Se exposure also led to insulin resistance in rats, which was attributed paradoxically to both 
ROS production and attenuated ROS55. Moreover, 16 weeks of Se supplementation in pigs on 
an already Se adequate diet resulted in a trend towards increased body weight and HOMA-IR 
score, a measure of insulin resistance56. This was accompanied by alterations in glucose and 
lipid metabolic pathways in insulin-sensitive tissues. With the exception of the skeletal muscle, 
GPX activity and TXNRD activities were largely unchanged in insulin-sensitive tissues in 
response to Se supplementation, suggesting selenoprotein expression was already saturated 
under Se adequate conditions. These results suggest the proclivity towards metabolic diseases 
in pigs receiving supranutritional Se doses may be a result of nonspecific incorporation of 
selenomethionine, rather than a consequence of increased selenoprotein activity. It is important 
to note that most of the parameters measured in this study only trended towards significance, 
and thus it was concluded that supranutritional Se contributes to but does not cause T2D. 
However, as the duration of the study was relatively short, it is premature to speculate whether 
significance would have been achieved under long-term supplementation. 
 In vitro studies in pancreatic islets and the mouse insulinoma derived β-cell line, MIN6, 
have demonstrated increased insulin content and secretion in response to Se treatment, leading 
to the hypothesis that Se protects islet function57. Higher levels of plasma Se were indeed found 
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to be associated with elevated serum insulin in mice54, but it is not known whether this is 
protective or detrimental. However, selenate treatment conferred protection to rat insulinoma 
cells, INS1, against streptozotocin-induced β-cell death58, suggesting the antioxidant properties 
of Se may be protective in the late stages of T2D. 
 These studies demonstrate that both over-supplementation and deficiency of Se can be 
associated with T2D risk, following a U-shaped curve that is consistent with the narrow range of 
upper and lower tolerable doses of Se. It appears that Se over-supplementation may promote 
T2D in an otherwise healthy animal. However, in diabetic animals which may have suboptimal 
Se status, Se appears to have beneficial effects by preventing further development of T2D 
complications. Additional studies will be useful in determining the appropriateness of Se 
supplementation with respect to T2D. 
1.8 Selenoproteins in T2D 
 Selenoproteins are important products that fulfill the catalytic effects of dietary Se. Thus, 
in order to clarify the discrepancies in the association between Se supplementation and T2D, it 
is necessary to understand the role of each selenoprotein in maintaining glucose homeostasis. 
This section will review what is currently known about the roles of selenoproteins that have been 
connected to metabolic diseases.  
1.8.1 Glutathione Peroxidase 1 
 Glutathione Peroxidase 1 (GPX1) is the primary cytosolic peroxide scavenger, reducing 
peroxides to water, and protecting the cell from free radical damage. Considered to be a stress 
responsive selenoprotein, GPX1 expression is sensitive to levels of Se intake. Overexpression 
of GPX1 in mice yielded surprising results, leading to reduced glucose clearance, 
hyperinsulinemia, hyperglycemia, and diminished insulin signaling59. Diet restriction alleviated 
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all metabolic symptoms except hyperinsulinemia, suggesting the functional role of GPX1 lies in 
regulating insulin production60. In this study, it was found that the H3 and H4 histones in the 
proximal promoter region of the insulin gene were hyperacetylated, ultimately leading to 
hyperinsulinemia. Although not shown directly, this hyperacetylation was speculated to be due 
to enhanced H2O2 scavenging. The importance of H2O2 in cellular signaling was established 
further when it was demonstrated that GPX1 null mice have increased insulin sensitivity in the 
muscle, resulting in a high fat diet-resistant phenotype61. The absence of GPX1 allowed for the 
oxidation of phosphatase and tensin homolog (PTEN), a member of the protein tyrosine 
phosphatase (PTP) family. Oxidation of PTEN inhibits its activity, sensitizing insulin signaling. 
 In contrast, several studies suggest that GPX1 might play a protective role against T2D. 
GPX1 overexpression in HIT-T15 cells protects against β-cell dysfunction induced by ribose 
treatment62. As ribose was found to induce oxidative stress in human islets, it is possible that 
GPX1 promotes β-cell survival through its ability to scavenge peroxides. Although constitutive 
GPX1-/- mice appear to preserve insulin signaling in response to an obesogenic diet, in the 
context of insulin secretion, GPX1 deficiency can be detrimental63. In the absence of GPX1, 
excess ROS in the pancreatic islets oxidize tyrosine-protein phosphatase non-receptor type 2 
(PTPN2), promoting signal transducer and activation of transcription 1 (STAT1) signaling which 
results in downregulating key enzymes of the insulin production and secretory pathway, such as 
pancreatic duodenal homeobox-1 (Pdx1). Inactivation of hepatic PTPs due to excess ROS also 
appears to promote obesity and T2D disease progression. In hepatocytes isolated from GPX1-/- 
mice, the presence of excess ROS inactivates PTPN2, which negatively regulates STAT5-
induced lipid synthesis64. Thus, hepatic GPX1 may prevent hepatic steatosis indirectly by 
regulating ROS levels. Further supporting the protective function of GPX1, the GPx mimetic, 
ebselen, was found to restore islet function in GPX1-/- mice through a peroxisome proliferator-
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activated receptor gamma coactivator 1-alpha (PGC-1α) dependent mechanism65. Nrf2 is a 
transcription factor that controls the transcription of antioxidant enzymes by interacting with an 
antioxidant response element (ARE). Several selenoproteins and selenoprotein synthesis 
factors were found to contain an ARE in their promoters, and are thus Nrf2-responsive66. GPX1 
levels were found to be suppressed when mice were fed a high fat diet due to 12-lipoxygenase 
activity, which was found to inhibit Nrf2 nuclear translocation67. Pancreatic islet specific 12-
lipoxygenase deletion resulted in GPX1 upregulation in response to high fat feeding. The 
resulting reduction in oxidative stress was found to be beneficial in preserving islet β-cell 
function under high fat diet consumption in mice. To corroborate these studies, a genetic 
polymorphism in the GPX1 gene which results in lower GPx activity, was found to correlate with 
increased incidence of metabolic syndrome in a cohort of Japanese men68. 
 Both GPX1 overexpression and deficiency appear to have negative effects in metabolic 
diseases. These findings are aligned with the U-shaped therapeutic dose effect of Se intake. 
However, the function of GPX1 is tissue dependent, exhibited by the differences in outcome of 
GPX1 deficiency in the muscle61, liver64, and pancreatic islets63. Increased understanding of 
tissue-specific functions of GPX1 will improve our knowledge of the role GPX1 plays in 
metabolic diseases. It is also important to note the GPX1 response may also have a timing 
specific component in that excess GPX1 in the pre-disease state may promote disease 
pathogenesis. The disease state, however, may suppress GPX1 expression.  
1.8.2 Selenoprotein P 
 In humans, a positive correlation between hepatic SELENOP expression and T2D has 
been reported69. In this same study, increased hepatic SELENOP mRNA expression was also 
associated with reduced glucose tolerance and higher fasting glucose levels, which are 
indicative of insulin resistance. However, it is important to note that serum SELENOP levels 
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become saturated at high Se intake70. One limitation of this study69 is that the patients’ Se intake 
levels were not reported. Likely, the usefulness of SELENOP as a biomarker is limited to 
subjects who do not receive an optimal Se intake. Additionally, since Se deficiency has been 
reported in T2D patients43, it is possible that SELENOP mRNA expression is elevated in the 
diseased state, as Se transport will be in higher demand. Thus, the elevation of SELENOP may 
be a secondary effect of T2D, rather than a cause. Nevertheless, adiponectin, an adipokine with 
anti-diabetic effects71, was found to be inversely correlated with serum SELENOP levels in T2D 
patients72. Moreover, elevated serum SELENOP levels were positively associated with carotid 
intima-media thickness and C-reactive protein, both of which are predictors for cardiometabolic 
disease73. Studies of SELENOP genetic variants reveal SELENOP polymorphisms to be 
associated with fasting insulin and the acute insulin response74. Taken together, SELENOP 
appears to be involved in glucose homeostasis, although direct conclusions cannot be made 
due to the correlative nature of these studies.  
 Mouse models and cell lines have been used to delineate the mechanistic relationship 
between SELENOP and carbohydrate metabolism. For example, studies in HepG2 cells 
revealed that hepatic SELENOP mRNA and promoter activity are under the control of insulin 
and a supramolecular complex composed of PGC1α, forkhead box protein O1 (FoxO1a), and 
hepatocyte nuclear factor 4 alpha (HNF-4α), which also regulates gluconeogenic enzymes 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase)75. Thus, 
an increase in SELENOP expression is likely positively correlated with hepatic 
gluconeogenesis. Additionally, SELENOP was found to negatively regulate insulin signaling in 
the liver, through 5' adenosine monophosphate-activated protein kinase (AMPK) inactivation in 
female mice69. SELENOP also downregulates insulin signaling in the muscle, although the 
mechanism remains unclear. Mice with SELENOP deletion (SELENOP-/-) were found to be 
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protected from diet induced obesity and insulin resistance. In a follow-up study, SELENOP-/- 
mice were found to be protected from the drop in serum adiponectin levels in response to a 
high-sucrose, high-fat diet, although adiponectin levels were not equal to those observed in 
untreated wild-type controls. This implicates a partial, but direct role for SELENOP in regulating 
adiponectin72. Because SELENOP is associated with gluconeogenic enzymes and 
downregulation of the insulin signaling pathway, it was proposed as a potential drug target. In 
fact, the commonly prescribed glucose lowering drug, metformin, suppresses SELENOP 
expression76. Further investigation demonstrated that metformin-induced inhibition of SELENOP 
expression occurs in an AMPK and FoxO3 dependent pathway77. 
1.8.3 Selenoprotein M 
 Selenoprotein M (SELENOM) is localized to the ER and is thought to participate in thiol-
disulfide exchange through its thioredoxin-like domain77. In vitro, SELENOM has been shown to 
regulate calcium signaling and protect against oxidative stress78. Because of its high expression 
levels in the brain, it was initially hypothesized that SELENOM offered neuroprotective 
properties, although simply deleting SELENOM in mice does not result in learning or memory 
deficits under a Se adequate diet79. Interestingly, SELENOM deletion in mice results in body 
weight gain and increased adiposity, suggesting SELENOM may play a role in energy 
metabolism. Immunohistochemistry further supported this hypothesis, as SELENOM was 
revealed to be highly expressed in the paraventricular nucleus and the arcuate nucleus of the 
hypothalamus, regions that are implicated in energy homeostasis. Leptin is an adipocyte-
derived peptide which activates receptors on the arcuate nucleus, allowing for crosstalk 
between the brain and fat depots80. The downstream effects of the leptin receptor are carried 
out via the Jak2-Stat3 pathway. Leptin resistance in the hypothalamus leads to alterations in 
energy homeostasis as the brain is no longer able to detect satiety. Although a direct 
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mechanistic relationship remains to be tested, SELENOM may regulate energy metabolism 
through regulating leptin signaling. Whole body SELENOM deletion in mice results in elevated 
circulating leptin levels and diminished phosphorylated Stat3 levels in the hypothalamus, which 
are indicative of leptin resistance79. Furthermore, ER stress has been implicated in 
hypothalamic leptin resistance80. As SELENOM is an ER-resident protein, there is a possibility 
SELENOM may promote leptin signaling by protecting against ER stress. Currently, it is 
unknown whether SELENOM contributes to human obesity. Given the possibility that 
SELENOM may promote leptin signaling by mitigating ER stress, further investigation into this 
relationship is warranted. 
1.8.4 Iodothyronine Deiodinase Family 
 The iodothyronine deiodinase family is composed of types 1-3 deiodinases (Dio1, Dio2, 
and Dio3), a group of selenoenzymes involved in thyroid hormone regulation. The thyroid 
prohormone 3,5,3’,5’ tetraiodothyronine (T4) is produced and secreted by the thyroid, but 
binding of thyroid hormone to its receptor requires the action of Dio1 or Dio2, which catalyzes 
deiodination of T4 to its active form, 3,5,3’ triiodothyronine (T3). In contrast to Dio1 and Dio2, 
Dio3 inactivates T3 and T4. 
 The role of thyroid hormone in energy expenditure has been well-documented81. It is 
therefore unsurprising that deiodinases are also implicated in energy metabolism. Indeed, 
genetic polymorphisms in the human DIO2 gene are associated with greater insulin resistance 
in T2D patients82. In mouse studies, Dio2 activation by cJun N-terminal kinase (JNK) in the 
anterior pituitary was found to be a critical component in diet-induced obesity83. On the other 
hand, whole-body Dio2 knockout mice (D2KO) develop insulin resistance on a standard 
laboratory  chow diet and are more susceptible to diet-induced obesity84. Moreover, D2KO mice 
on a high fat diet preferentially utilize carbohydrates as a fuel source and have lower serum free 
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fatty acid and β-hydroxybutyrate levels, suggesting that Dio2 is involved in fatty acid utilization. 
Additionally, the liver-X receptor (LXR), which is activated by 22(R)-OH-cholesterol, negatively 
regulates Dio2, further strengthening the case for Dio2 involvement in lipid metabolism85. 
 Thyroid hormone deactivation is also involved in energy homeostasis. Dio3 is expressed 
in pre-natal pancreatic tissue and appears to be important in β-cell development as Dio3 
knockout mice (D3KO) have reduced islet size and insulin content86,87. Dio3 activation has also 
been found to be important in GLP-1 mediated insulin potentiation88. Thus, tight regulation by 
deiodinases contribute to the maintenance of glucose homeostasis by ensuring tissue and time 
appropriate thyroid hormone activation.  
1.8.5 Selenoprotein T 
 Selenoprotein T (SELENOT) was first identified in silico, using an algorithm to identify 
SECIS elements in the human dbEST89. Containing a thioredoxin-like fold, SELENOT was 
proposed to possess redox activity90, but its precise function remains unknown. Bioinformatics 
analysis revealed SELENOT to be localized to the ER, possibly being trafficked to the plasma 
membrane91. SELENOT expression in mice appears to be highest during development, with 
SELENOT mRNA expression in most tissues decreasing in adulthood, except in endocrine 
tissues such as the thyroid, pituitary, testis, and thymus92. The pituitary adenylate cyclase 
activating polypeptide (PACAP) is a neuropeptide which increases cAMP through adenylate 
cyclase stimulation, having implications in a variety of cellular processes, including cell survival 
and secretory function. SELENOT was recently identified as a target of PACAP93. In 
differentiated rat pheochromocytoma PC12 cells, SELENOT is necessary for PACAP-
dependent neuroendocrine secretion by regulating intracellular Ca2+ levels. Many neuropeptides 
regulate energy homeostasis, such as neuropeptide Y (NPY)94, agouti-related peptide (Agrp)95, 
α-melanocyte stimulating hormone (α-MSH)96, among others. Identifying the neuropeptides 
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under SELENOT regulation could provide greater understanding of the connection between 
dietary Se and energy metabolism. Immunofluorescence demonstrated SELENOT to be highly 
expressed in the adult pancreatic β and δ-cells, indicating SELENOT may be involved in 
glucose homeostasis. Conditional knockout of SELENOT in the β-cell resulted in defective 
insulin secretion, suggesting SELENOT is critical to β-cell function. Studies in the glucose 
responsive murine β-cell line, MIN6, determined that PACAP-induced insulin secretion depends 
on SELENOT expression. This indicates that SELENOT may regulate blood glucose at multiple 
levels. Although SELENOT is expressed in other metabolic tissues such as the pituitary and 
thyroid92, the molecular function of SELENOT in these tissues is unknown. 
1.8.6 Selenoprotein S 
 Like SELENOT, Selenoprotein S (SELENOS) was first identified in silico, and was 
shown to localize to the plasma membrane24. Functionally, SELENOS has implications in ER-
associated degradation (ERAD)97, inflammation98, and the transport of multi-protein 
complexes99. In 2003, a novel protein, Tanis, was characterized as a glucose-regulated protein 
in Psammomys obesus, an animal model for T2D100. Tanis was found to be expressed in 
insulin-sensitive tissues such as adipose tissue, liver, and skeletal muscle. Through yeast two-
hybrid screening, Tanis was found to interact with serum amyloid A, a family of proteins 
associated with the acute-phase inflammatory response, which is typically elevated in T2D 
patients. Potentially, Tanis acts as a receptor for serum amyloid A. Tanis was later identified to 
be a SELENOS homolog24, leading to the hypothesis that SELENOS links inflammation to T2D. 
In support of this, a positive correlation between serum amyloid A levels and SELENOS 
expression in the skeletal muscle and adipose tissue of T2D patients was reported101. 
SELENOS appears to be dysregulated in the disease state, as hyperinsulinemia increases 
SELENOS mRNA expression in the adipocytes of T2D subjects but not healthy subjects. 
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Conversely, a different study found subcutaneous adipocyte SELENOS mRNA expression to 
increase in response to insulin in both obese and lean subjects102. This study also failed to find 
a correlation between serum amyloid A and SELENOS expression. However, SELENOS 
expression was found to be higher in obese subjects, with increased subcutaneous SELENOS 
expression in obese subjects associated with BMI, sagittal diameter, serum HDL, triglycerides, 
insulin, and insulin resistance. Additionally, SELENOS polymorphisms were correlated with 
higher diastolic blood pressure and circulating insulin. These individuals were also at a higher 
risk for cardiovascular disease. Taken together, these studies support a role for SELENOS in 
metabolic diseases, however, the specific mechanism remains to be elucidated. 
 One possibility is that SELENOS plays a protective role. For instance, SELENOS has 
been shown to be upregulated in the hepatoma-derived HepG2 cells in response to glucose 
deprivation103, albeit the physiological relevance is debated, as the low glucose concentration 
tested was 2 mM, well below the range of normal blood glucose levels in humans. However, in 
HepG2 cells, SELENOS was also found to increase in response to ER stress, while 
overexpression of SELENOS conferred protection against oxidative stress in the mouse-
insulinoma derived MIN6 cells. Thus, SELENOS may play a protective role, counteracting 
oxidative stress in T2D development. 
1.9 Sex Differences in Se and T2D 
 Sex differences in Se uptake and selenoprotein expression patterns have been 
described and are reviewed elsewhere104. Given the sexual dimorphism in Se regulation, it is 
unsurprising that human clinical trials hint at the possibility that the relationship between Se and 
T2D is sex-specific. In the NPC trial, the increased T2D risk in response to Se supplementation 
was limited to males49, although one limitation of this study is that females were severely 
underrepresented, comprising only 25% of the subjects. Nevertheless, the NHANES III, found a 
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correlation between T2D risk and high Se in males, but not females46, a finding which was 
supported by NHANES 2003–200447. In contrast, but still supporting the hypothesis that the Se 
and T2D interrelationship is sex-specific, Akbaraly et al.43 reported a correlation between lower 
baseline Se and T2D incidence among elderly French men, but not women. Understanding sex 
differences in the biological function and regulation of selenoproteins may explain the sexually 
dimorphic results of Se and T2D. Unfortunately, studies involving sex differences in the 
contribution of individual selenoproteins to metabolic diseases are limited. This section will 
highlight some of the known sex differences reported in selenoprotein regulation of energy 
metabolism. 
 GPX1 polymorphisms were correlated with increased MetS incidence in Japanese men, 
but not women68. The initial studies that investigated obesity and hyperinsulinemia in GPX1 
overexpressing mice only utilized male mice, thus it is unknown whether the effect of GPX1 
overexpression in mice is sex-specific59,60. Serum SELENOP levels were elevated in diabetic 
men and women compared to healthy subjects69. However, subsequent studies investigating 
SELENOP and insulin resistance were restricted to female mice. Whether SELENOP directly 
induces insulin resistance through AMPK in male mice is unknown. In the same study, 
SELENOP deficiency was found to produce an obesity-resistant phenotype in male mice, but 
female mice were left out due to inconsistencies in the results. Although sex differences in the 
association between SELENOS and metabolic diseases have not yet been described, there are 
sex differences in the amount of Se necessary to reach maximal murine hepatic SELENOS 
expression105. This discrepancy in SELENOS expression may contribute to the differences 
observed in the effectiveness of Se supplementation in a model of septic shock. We must not 
exclude the possibility that the sex differences in the regulation of SELENOS expression might 
result in sex-specific outcomes in metabolic diseases. 
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 The studies in Scly-/- mice focused primarily on males as it was observed that female 
Scly-/- tended to display a mild metabolic phenotype, whereas the differences in males were 
more pronounced38. A plausible explanation is that the Se metabolic pathway does not interfere 
with energy metabolism in females. Recent evidence from mice with combined Scly and 
SELENOP deletion (Scly-/-SELENOP-/-) demonstrates that female mice are less dependent on 
the Se recycling pathway for neurological function, as female Scly-/-SELENOP-/- mice do not 
exhibit the severe neurological deficits reported in male Scly-/-SELENOP-/- mice35. As the 
primary Se source for the brain and testes, SELENOP is particularly critical for these tissues, 
supplying Se via the ApoER2 receptor106,107. Absence of either SELENOP or ApoER2 results in 
a similar phenotype, consisting of behavioral deficits and male infertility. Strikingly, castration of 
male Scly-/-SELENOP-/- mice was shown to attenuate the neurological dysfunction present in 
uncastrated mice, offering a novel representation of the competition between the brain and 
testes for Se supply79. In the context of metabolic disease, it is conceivable that sequestration of 
available Se by the testes occurs at the expense of metabolic tissues, leading to altered glucose 
homeostasis in males. 
1.10 Introductory Highlights  
 Se undoubtedly has numerous benefits to human health, with implications in T2D51, 
cancer108, male fertility109, and neurological function110, among others. However, the association 
of high Se intake and T2D in human epidemiological studies and clinical trials raises concerns 
regarding the practicality of Se supplements. Animal studies have offered mechanistic insight, 
identifying potential links between Se and T2D, namely oxidative stress. In addition, because 
the effects of Se occur through the enzymatic actions of selenoenzymes, the individual 
selenoproteins (GPX1, SELENOP, SELENOM, DIO2, SELENOT, SELENOS) that have been 
connected to T2D provide important information on the details of Se in T2D. Moreover, the Se 
22 
 
metabolic pathway has been suggested to influence carbohydrate and lipid metabolism, 
strengthening the idea that Se does in fact play a role in T2D. The aforementioned sexually 
dimorphic association between Se and metabolic diseases reveals the complexity of Se 
processes. In order to reduce potentially undesirable effects of Se supplementation, and to 
further improve dietary guidelines for Se, a more comprehensive understanding of Se 
metabolism and selenoproteins in both male and female subjects is essential. 
 
1.11 Hypothesis 
Scly regulates insulin secretion and whole-body glucose homeostasis in male mice, but not 
females.  
 
1.12 Specific Aims 
Specific Aim 1: Characterize the role of Scly in pancreatic islet physiology. 
Working hypothesis: Scly is present in the insulin producing β-cells and its regulation of 
selenoprotein expression is critical in pancreatic islet function. 
Rationale: We previously reported that Scly-/- mice develop a metabolic syndrome-like 
phenotype, with remarkably high fasting serum insulin levels38. This suggests that alterations in 
Sec decomposition may lead to pancreatic islet dysfunction. While selenoproteins such as 
GPX1, SELENOT, Dio3 and SELENOS have been shown to play important roles in insulin 
secretion, the impact of Se metabolism remains unexplored. Therefore, the goal of this aim is to 
determine whether Scly-dependent regulation of selenoprotein expression is necessary for 
glucose-stimulated insulin secretion (GSIS). 
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Specific Aim 2: Investigate the sex differences in Scly regulation of energy metabolism and 
determine the contributing role in male reproduction. 
Working hypothesis: Scly-/- mice display sex differences in their metabolic phenotype, and these 
differences can be accounted for by the Se demands of the male reproductive system. 
Rationale: Scly-/- mice appear to develop metabolic syndrome in a sex-specific manner, and thus 
may serve as a model to understand sex differences in Se metabolism and the onset of 
metabolic syndrome in humans. In a previous study, castration was found to rescue 
neurological effects in Scly-/-SELENOP-/- mice, elucidating a mechanism in which the testes act 
as a Se sink, worsening the outcome for male mice. Therefore, the effects of castration were 
tested on Scly-/- mice to determine whether Se sequestration by the testes negatively impacts 
glucose homeostasis.    
 
1.13 Significance 
 The studies in this dissertation were aimed at establishing a novel role for Scly in islet 
function and to clarify the potential sex-specific regulation that was previously reported. Overall, 
these studies improve our understanding of Se in the development of metabolic diseases, which 
will aid improving general guidelines for appropriate Se intake. The significance of this project 
on public health is that the obtained knowledge could facilitate identification of undesirable 
effects mediated by the Se metabolic pathway during drug discovery. 
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CHAPTER 2. THE ROLE OF SELENOCYSTEINE LYASE IN PANCREATIC ISLET FUNCTION 
2.1 Introduction 
 Regulation of blood glucose levels relies heavily on insulin secretion and its action on 
target tissues. In the early stages of T2D, insulin production is increased to compensate for 
insulin resistance in order to maintain regulation of glucose levels. The main site of insulin 
production is the β-cell, one of several cell types present in the pancreatic islets. As the disease 
progresses, β-cell mass and function decline, and hyperglycemia ensues. Thus, maintaining 
normal islet function is critical to reversing or slowing the progression to T2D. While the main 
insulinotropic agent is glucose, many other nutrient signals stimulate insulin secretion by 
enhancing vesicle release.  
 
 Se is an essential dietary micronutrient whose physiological functions are dependent 
upon its incorporation into selenoproteins. In epidemiological studies, higher serum Se levels 
have been associated with elevated fasting insulin47. Additionally, treatment of the mouse 
insulinoma-derived MIN6 cells and rat islets with selenite improves insulin production and 
secretion through the upregulation of insulin promoter factor 1 (Ipf1), a key transcription factor in 
insulin synthesis57. To corroborate these findings, the overexpression of GPX1, a selenoenzyme 
whose expression is particularly sensitive to Se levels, results in primary hyperinsulinemia in 
mice, a condition in which hyperinsulinemia precedes insulin resistance. It was proposed that 
enhanced H2O2 scavenging by GPX1 resulted in hyperacetylation in the insulin promoter PDX1, 
leading to increased insulin synthesis60. On the other hand, the expression of selenoproteins 
DIO3 and SELENOT are necessary for β-cell development and GSIS, as their respective 
knockout mice present with decreased β-cell mass and impaired insulin secretion86,111. 
Additionally, SELENOS overexpression protected mouse insulinoma-derived MIN6 cells against 
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H2O2 induced cell death, implicating a role for SELENOS in protecting β-cells against oxidative 
damage. Further investigation is necessary to clarify the role of Se and selenoproteins in islet 
function. 
 
 In the β-cell, nutrients are metabolized and participate in pathways which produce 
second messengers that enhance insulin vesicle release112. Scly is an important component of 
Se metabolism as it is involved in Sec decomposition, cleaving Sec to produce alanine and 
selenide. Moreover, Scly may be involved in the Se salvage pathway as the produced selenide 
can re-enter the Sec pool to be repurposed for selenoprotein synthesis. We previously 
generated and characterized mice with whole-body Scly deletion which provided insight to the 
role of Scly in hepatic carbohydrate and lipid metabolism38,40. Of particular interest, Scly-/- mice 
exhibit remarkably elevated fasting insulin levels. Thus, we hypothesized that Scly is a critical 
factor that couples Se and/or selenoproteins to insulin secretion. 
 
 Unlike Scly, sulfur pathway enzymes lack the ability to distinguish sulfur molecules from 
their Se analogs. In the glutathione synthesis pathway, Cys/Sec can be converted to glutathione 
through the rate limiting enzyme glutathione cysteine ligase, which is composed of the 
regulatory and the catalytic subunits Gclm and Gclc, respectively. Cysteine degradation involves 
the cysteine desulfurase, Nfs1. The enzymes cystathionine β-synthase (Cbs) and cystathionine 
γ-lyase (Cth), act sequentially to convert homocysteine to Cys in the reverse trans-sulfuration 
pathway. In the methionine cycle, methyltransferase (Mtr) converts homocysteine to methionine. 
It is unknown whether sulfur pathways can compensate for Scly deletion.  
 
 The main goal of this study was to investigate the role of Scly in pancreatic islet 
physiology. We found that Scly is highly expressed in the pancreatic islet and we therefore 
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tested whether Scly influences GSIS. We also measured selenoprotein expression to determine 
if any effects Scly has on islet function occurs through a selenoprotein-dependent mechanism. 
To determine whether sulfur pathways could compensate for Scly deletion, we employed qPCR 
to measure gene expression changes that could explain alterations in the insulin secretory 
pathway. 
 
2.2 Methods 
2.2.1 Animals 
 Whole-body male Scly-/- mice were generated and backcrossed to WT C57BL/6N mice 
as previously described38. All mice were bred and housed in the animal facility at University of 
Hawaii. Mice were weaned onto a special diet containing adequate (0.25 ppm) or low (0.08 
ppm) levels of Se in the form of sodium selenite (Research Diets Inc., New Brunswick, NJ) and 
maintained on a 12-h light/dark cycle. Unless otherwise noted, animals were euthanized via CO2 
asphyxiation. All procedures were approved by the Institutional Animal Care and Use 
Committee of the University of Hawaii. 
 
2.2.2 Cell culture 
 MIN6 cells are a murine pancreatic β-cell line that is useful in studying insulin secretion, 
as it maintains β-cell characteristics, and has been shown to secrete insulin in response to 
glucose treatment113. MIN6 cells were purchased from AddexBio (San Diego, CA) and cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM; Cellgro, Manassas, VA) with 15% fetal bovine 
serum (FBS; Invitrogen, Carlsbad, CA), 1X Penicillin-Streptomycin-Glutamine (Cellgro, 
Manassas, VA) at 37°C and 5% CO2. FBS was tested for total Se content and found to contain 
320 nM Se.  
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2.2.3 Scly knockdown 
 For Scly knockdown, CRISPR/Cas9 constructs were designed and purchased from the 
Gene Editing Institute at the University of Delaware. Scly-targeting gRNA was cloned into 
px458, which contains an eGFP tag. MIN6 cells were seeded and grown in a T-75 flask. 
Constructs were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA). MIN6 cells 
were collected and fluorescence-activated cell sorting (FACS) was performed with the 
FACSAria II (BD Biosciences, San Jose, CA) to sort for all GFP+ cells 48 hours post-
transfection. Cells were allowed to recover and grow for one week prior to experimentation. 
Knockdown was confirmed using Western Blot. 
 
2.2.4. Scly activity 
 Scly activity was assessed as previously described31, by measuring the absorbance of 
selenide that has been precipitated by lead acetate.  
 
2.2.5 Immunofluorescence 
 Pancreases were fixed in 4% paraformaldehyde, paraffin embedded, and sectioned at 5 
μm thickness. Antigen unmasking was completed with boiling in 0.1M citrate buffer, pH 6 (0.1M 
anhydrous citric acid, 0.05% Tween-20) for 4 min. Endogenous mouse antigen was blocked 
using 20 μg/ml unconjugated affinity pure Fab fragment goat anti-mouse IgG (Jackson 
ImmunoResearch Inc., West Grove, PA) and triple-labeled in parallel using specific primary 
antibodies and Alexafluor conjugated secondary antibodies (Jackson ImmunoResearch Inc., 
West Grove, PA). Coverslips were mounted using mounting media with the nuclear marker 4',6-
diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA). Fluorescence was 
detected using the Zeiss LSM 5 Pascal Confocal microscope (Oberkochen, Germany). DAPI 
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was detected using the Zeiss Axioskop 2 (Oberkochen, Germany) 
 
2.2.6 Subcellular fractionation 
 Nuclear and cytosolic separation was performed in whole pancreas as described 
previously114. Briefly, tissue was minced over ice, re-suspended in a hypotonic solution (STM 
buffer: 250mM Sucrose, 50mM Tris-HCl pH 7.4, 5mM MgCl2, 1X protease/phosphatase 
inhibitor) and homogenized using a GT21-18 heavy duty laboratory stirrer (G.K. Heller 
Company, Floral Park, NJ) to disrupt cell membrane. Homogenate was centrifuged and the 
supernatant (cytosolic fraction) was precipitated with acetone. The pellet was washed, 
resuspended in nuclear extraction buffer (20mM HEPES pH 7.9, 1.5mM MgCl2, 0.5M NaCl, 0.2 
mM EDTA, 20% glycerol, 1% Triton X-100, 1X protease/phosphatase inhibitor) and sonicated to 
disrupt the nuclear membrane. Fractionation was confirmed via Western Blot using anti-GAPDH 
(Abcam, Cambridge, MA) as the cytosolic control and anti-Histone H3 (CST, Danvers, MA) as 
the nuclear control. 
 
2.2.7 Islet isolation 
 Pancreatic islets were isolated using a modified version of the collagenase method as 
previously described115. Briefly, after euthanasia, a collagenase and neutral protease solution 
(CIzyme RI, VitaCyte, LLC, Indianapolis, IN) was perfused into the pancreas via the common 
bile duct and excised. Pancreases were kept on ice for not more than one hour before digestion. 
Digestion was performed in a water bath at 37°C for 18 min and terminated with the addition of 
RPMI 1640 (Cellgro, Manassas, VA) with 10% newborn calf serum (Gibco, Waltham, MA). Islets 
were separated with a density gradient using lymphocyte separation medium (Cellgro, 
Manassas, VA) and handpicked for purity. 
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2.2.8 Glucose-stimulated insulin secretion (GSIS), insulin content, and DNA concentration 
 Handpicked islets from 8-week-old male mice were cultured overnight in RPMI 1640, 
10% FBS (Invitrogen, Carlsbad, CA), and 1% penicillin-streptomycin (Cellgro, Manassas, VA) at 
37°C with 5% CO2 and 80% humidity. GSIS was performed using a static incubation method as 
previously described116. Islets were transferred to Krebs-Ringer bicarbonate (KRB) buffer with 
low glucose (2.8 mmol/L) and incubated sequentially for 1 hour at 37°C in the following order: 
twice in KRB buffer with low glucose and once with KRB buffer with high glucose (16.8 mmol/L). 
Islets were washed twice with KRB buffer with low glucose between each incubation. Media was 
collected after the second low glucose incubation to determine basal insulin secretion and after 
the high glucose incubation for GSIS, which was measured using a mouse ELISA kit (ALPCO, 
Salem, NH). Islets were collected and resuspended in 500 μl of PBS and sonicated with 3x 10s 
pulses over ice. 250 μl of the supernatant was used to determine insulin content via ELISA while 
the other half was used to determine DNA concentration. DNA was extracted and concentration  
was determined using the Quant-iT Picogreen kit (ThermoFisher, Grand Island, NY) according 
to manufacturer’s instructions. 
 
2.2.9 Western blot 
 Handpicked islets were washed twice with ice cold PBS, re-suspended in Sigma 
CelLytic™ MT (St. Louis, MO), incubated over ice for 20 min, and vortexed at maximum speed 
for 15s. Protein concentration was measured using the Bradford method with the Bio-Rad 
Protein Assay Reagent (Hercules, CA). 20 μg of total protein were separated on a 4-20% Tris-
Glycine polyacrylamide gel (Bio-Rad, Hercules, CA), transferred to an Immobilon-FL membrane  
Biosciences, Lincoln, NE) and incubated in primary antibody overnight at 4°C. Blots were 
washed 3x 5 min in 0.1% Tween-20 in PBS and incubated in the appropriate IRDye secondary 
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antibody (Li-Cor Biosciences, Lincoln, NE) for 30 min. An Odyssey IR imaging system (Li-Cor 
Biosciences, Lincoln, NE) was used for detection and analysis was complete on the Image  
Studio v4.0 software (Li-Cor Biosciences, Lincoln, NE).  
 
2.2.10 qPCR  
 Synthesis of cDNA was completed using a High Capacity cDNA Reverse Transcription 
kit (Applied Biosystems, Waltham, MA) according to manufacturer’s instructions. SYBR green 
(Invitrogen, Carlsbad, CA) and Roche LightCycler 480II were used to detect mRNA levels. 
Results were analyzed via the ΔCt method using a reference gene, which is a variation of the   
2-ΔΔCt method. All samples were normalized to the housekeeping gene cyclophilin B (Cphn2), 
which was unaffected by genotype. Primer efficiencies between 1.95 and 2.05 were considered 
to be acceptable. Primer sequences are listed in Table 2. 
 
2.2.11 Statistical analysis 
 Unless otherwise noted, data were analyzed and graphed with GraphPad Prism 5 
(GraphPad Software Inc., La Jolla, CA) using the appropriate statistical tests. The statistical 
tests are referred in figure legends.  
 
 
Gene Forward (5‘>3‘) Reverse (5‘>3‘) 
Cphn2 GGAGATGGCACAGGAGGAA GCCCGTAGTGCTTCAGCTT 
Gclc CTCCAGTTCCTGCACATCTACC AACATGTACTCCACCTCGTCAC 
Gclm CCACCAGATTTGACTGCCTTTG AGAGCAGTTCTTTCGGGTCATT 
Nfs1 TCACAACCCAGACAGAACACAA GATGGCAGCCTCTAGTTCCTTT 
Mtr GCAACAAGAGTCATTAAGGAAA AGGAGAAGGATAAGTTGGAAAG 
Cbs ATGAGTATGGAGAAGGTGGAT GAATGTGAGAATTGGGGATTTC 
Cth TGCCACCATTACGATTACCCAT TTGGTGCCTCCATACACTTCAT 
Table 2. Quantitative PCR primer sequences. 
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2.3 Results 
2.3.1 Scly is present in the β-cells of the pancreatic islets 
 Scly-/- mice have been shown to develop remarkable fasting hyperinsulinemia38. Thus, 
we hypothesized that Scly regulates insulin secretion and that alternations in β-cell function 
contribute to the metabolic dysfunction observed in Scly-/- mice. To test this hypothesis, we first 
used immunofluorescence to investigate Scly expression within β-cells of the pancreatic islet, 
the main site of insulin production and secretion. Our images revealed that Scly expression 
largely overlaps with insulin expression in the islet (Figure 2Error! Reference source not 
found.), although not exclusively, as we also observed overlap with glucagon expression, which 
is produced and secreted by the α-cell. Nevertheless, our images suggest that Scly is localized 
where it can possibly interact with components of the insulin synthesis and/or secretion 
pathway.  
 
2.3.2 Subcellular localization of Scly 
 Based on the established role of Scly, it has been predicted that Scly is localized in the 
cytosol. However, in our confocal images (Figure 3), Scly appeared to mimic a nuclear staining 
pattern. Using the nuclear marker DAPI as a counterstain, we checked for localization of Scly 
within the nucleus. To our surprise, Scly was co-localized with DAPI within the islet (Figure 3A). 
To further confirm this Scly subcellular localization, we separated nuclear and cytosolic extracts 
from whole pancreata. In contrast to our immunofluorescence images, Scly was restricted to the 
cytosolic fraction (Figure 3B). 
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2.3.3 Scly has opposing effects on GSIS in MIN6 cells versus pancreatic islets 
 Following confirmation that Scly is expressed in the pancreatic islet, we next tested the 
effects of Scly deletion on GSIS. To verify that MIN6 is an appropriate model to study Scly 
function in β-cell physiology, Scly activity was measured. In accordance with previous studies117, 
Scly activity was detected under low Se conditions and significantly decreased under Se 
adequate conditions (p<0.0001) (Figure 4A). Scly expression was knocked down using 
CRISPR/Cas9 and confirmed via Western Blot (Figure 4B). Because all GFP+ cells were sorted 
together, low levels of Scly expression can be explained by the fact that CRISPR/Cas9 does not 
induce a mutation at 100% efficiency. 
Figure 2. Scly is highly expressed in the pancreatic islet.           Representative confocal image 
depicting an islet from 10-week-old male WT mice fed a Se adequate diet. As controls, 
staining procedure was performed without primary antibody, as well as with sections from 
Scly-/- mice. Scly appears to be most strongly expressed within the pancreatic islet. Glucagon 
is indicated in blue, insulin in red, and Scly in green. White arrows indicate artifacts. Image 
representative of n=3. 
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 Next, we measured GSIS in MIN6 cells with diminished Scly expression. While there 
was a main effect of glucose treatment in GSIS, there was no effect of genotype (Figure 4C).  
Nevertheless, the insulin response was approximately 1.8 times greater when Scly was knocked  
down. Surprisingly, there were no differences in total insulin content (Figure 4D).  
 
 Because differences in GSIS among MIN6 and primary cells have been reported118, we 
repeated GSIS in islets isolated from WT and Scly-/- mice. In contrast to our results in MIN6 
cells, WT islets had nearly a two-fold greater insulin response to glucose than Scly-/- islets 
(Figure 4E). Insulin content among the WT and Scly-/- remained unchanged after GSIS (Figure 
4F), indicating insulin synthesis and production was unaffected by Scly-/- deletion in pancreatic 
islets. 
Figure 3. Contrasting cellular localization of Scly in immunofluorescence images and 
subcellular fractionation.           (A) Representative immunofluorescent image of an islet from a 
10-week-old male mouse. Scly is indicated in green, insulin in red, and DAPI in blue. Scly 
appears to colocalize with DAPI (cyan). (B) Western Blot of cytosolic, C and nuclear, N 
fractions from whole pancreas of 10-week old mice. Scly expression was detected only in 
the cytosolic fraction. Detection of GAPDH and histone H3 were used as controls for 
cytosolic and nuclear purity, respectively, n=3. 
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                 (A) Scly activity under Se deficient (3 nM 
Se) and adequate (70 nM Se) conditions for 24 hours, t-test: ***p<0.001, n=6. (B) Western 
Blot confirming successful knock-down using CRISPR/Cas9. The low level of Scly in the 
knock-down is a result of differences in homologous recombination efficiencies. Different 
lanes are replicates for each condition. (C) Insulin secretion at baseline (2.5 mM glucose) and 
after high glucose (16.7 mM) conditions. Two-way ANOVA showed a main effect of glucose 
(F1,6=20.15, p=0.004), but not knockdown (F1,6=0.41, p=0.54), or interaction (F1,6=2.70, 
p=0.15), n=4, and (D) insulin content, t-test: ns (not significant). (E) GSIS in isolated islets 
from 8-week-old male WT and Scly-/- mice. 2-WA showed a main effect for glucose 
(F1,11=25.34 p=0.0004) but not genotype (F1,11=1.61 p=0.23) or interaction (F1,11=1.59 p=0.23). 
Bonferroni’s correction: *p<0.05 **p<0.01, n=7. (F) Insulin content, ns. All data are 
represented as means ± S.E.M. 
Figure 4. GSIS in MIN6 cells and isolated islets. 
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2.3.4 Scly does not affect selenoprotein expression under Se adequate conditions  
 We previously reported that hepatic selenoprotein expression is largely unaffected by 
the absence of Scly when Se supply is adequate38,40. However, Se distribution among tissues 
and selenoprotein expression regulation occur in a hierarchical manner104. Thus, it is possible 
that the hepatic selenoprotein profile does not reflect the conditions in the pancreatic islet. We 
therefore measured selenoprotein levels by Western Blotting in isolated islets from 8-week-old 
WT and Scly-/- mice. We measured GPX1 and SELENOS levels based on their confirmed roles 
in islet function, but we did not detect differences between WT and Scly-/- islets (Figure 5A-C). 
Additionally, we measured SEPHS2 levels because it has been identified as a potential 
interactor of Scly and hypothesized to work as part of a complex in selenoprotein biosynthesis33. 
             
(A) Representative Western Blot image showing indicated selenoprotein expression. (B-D) 
Quantification of the expression of selenoproteins normalized to β-actin levels. All data are 
represented as means ± S.E.M., t-test was used to calculate p values, n=4. 
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Figure 5. Islet selenoprotein expression in 8-month-old WT versus Scly-/- mice. 
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Nevertheless, no observable changes were detected in SEPHS2 protein expression (Figure 
5A,D). Taken together, our data suggest that when Se demands are fulfilled, Scly does not 
influence selenoprotein expression in the pancreatic islet. 
 
2.3.5 Sulfur pathway enzyme mRNA expression is unchanged in response to Scly deletion 
 We next determined whether glutathione synthesis and cysteine degradation pathways 
can compensate for the absence of Scly because of their ability to further metabolize Cys/Sec. 
Thus, we measured islet mRNA expression of Gclm, Gclc, and Nfs1 via qPCR, but did not 
observe any significant differences (Figure 6). Additionally, we considered the possibility that 
sulfur pathways such as the reverse trans-sulfuration pathway and methionine cycle could be 
affected by the absence of Scly. However, qPCR did not reveal any noticeable differences in 
Mtr, Cbs, or Cth gene expression (Figure 6). 
Figure 6. Gene expression of sulfur pathways in islets of 8-week-old male WT vs. Scly-/-
mice.          Fold changes of genes in the glutathione synthesis pathway (Gclm, Gclc), cysteine 
degradation (Nfs1), methionine cycle (Mtr), and reverse trans-sulfuration pathway (Cbs, Cth). 
WT gene expression is indicated by the black dotted line. Samples were normalized to the 
housekeeping gene Cphn2. All samples are represented as means ± S.E.M., n=3 pooled 
samples per group.  
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2.4 Discussion 
 We previously demonstrated that Scly-/- mice develop hyperinsulinemia. To the best of 
our knowledge, the present study is the first to demonstrate that Scly is present in the 
pancreatic islet. We found that Scly has opposite effects in MIN6 cells and isolated islets, 
potentially indicating that Scly is physiologically important not only in β-cells but in the other cell 
types that compose the pancreatic islet. Expression of GPX1, SELENOS, and SEPHS2 were 
unaffected, indicating Scly is not a critical factor in the biosynthesis of these selenoproteins 
under Se adequate conditions in the pancreatic islet. Moreover, our qPCR results do not 
support a compensatory role for sulfur metabolic pathways in the absence of Scly. 
 
 Our immunofluorescence studies revealed that Scly was co-localized with DAPI staining 
(Figure 3A) but Scly could be detected only in the cytosolic fraction when subcellular 
fractionation was employed (Figure 3B). Selenoprotein synthesis factors such as SBP2 and 
eEFSec express nuclear localization and export signals and participate in nucleocytoplasmic 
shuttling, a mechanism which increases Sec incorporation efficiency119. It is possible that Scly is 
involved in nucleocytoplasmic shuttling, but Scly does not appear to have a nuclear 
export/localization signal117. This does not exclude the possibility that Scly is part of a molecular 
complex that facilitates shuttling. Moreover, we must consider that Scly may be localized near 
the surface of the nuclear membrane, but not in the nucleus. Further investigation would provide 
a clearer overview of the biological significance of Scly subcellular localization
 
 Because Scly-/- mice present with fasting hyperinsulinemia, we hypothesized that the 
insulin secretory pathway is dependent on Scly function. Our results in MIN6 cells indicated that 
Scly knockdown-enhanced GSIS (Figure 4C), but isolated Scly-/- islets had impaired GSIS when 
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compared to WT islets (Figure 4E). Since Scly-/- mice have higher fasting serum insulin levels, 
diminished GSIS could be due to insulin lost during fasting. If this were the case, we would 
expect to see higher baseline secreted insulin. Nevertheless, it may be useful to measure 
fasting insulin content. Hyperinsulinemia may also lead to β-cell exhaustion, in which insulin 
secretion loses efficacy. This could be tested by measuring expression and activity of various 
components of the insulin secretory pathway such as glucokinase, Pcx, and PDH, among 
others. MIN6 cells begin to lose their β-cell characteristics and display impaired GSIS at high 
passage numbers120. One limitation to our study is that our cell line was purchased through a 
manufacturer that could not provide information on how many passages our cells had previously 
undergone. If these cells were at a high passage number, alterations in key β-cell genes could 
account for the differences in GSIS response we observed. 
 
 One of the advantages of utilizing the MIN6 cell line is that it is a homogeneous 
population of cells which maintain β-cell like characteristics. While this is undoubtedly useful in 
understanding signaling pathways in the β-cell, it may not be the most physiologically relevant 
model in terms of insulin secretion. This is because intra-islet interaction via paracrine signaling 
also contributes to insulin secretion regulation and β-cell survival. In fact, a study seeking to 
better understand paracrine signaling loops in the islet found 233 candidates for secreted 
factors using a bioinformatics database search121. Considering Scly expression is not restricted 
to β-cells (Figure 2), it is conceivable that Scly has direct or indirect consequences on these 
paracrine factors, influencing the outcome of GSIS in MIN6 versus isolated islets. Future studies 
evaluating the changes in secreted factors and the expression of their receptors within the islet 
in Scly-/- mice may clarify the paracrine pathways that may be regulated by Scly. 
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 Our measurements of islet selenoprotein expression mirrored previous findings in the 
liver that under Se adequate conditions, Scly does not appear to influence selenoprotein 
biosynthesis, at least for GPX1, SELENOS, and SEPHS2 (Figure 5). This suggests that the 
pancreatic islet does not have priority over other metabolic tissues such as the liver in the 
context of seleneoprotein biosynthesis. 
 
 Because Sec is toxic, when selenoproteins undergo proteolysis, the released Sec must 
be further metabolized to avoid damaging effects122. As the only identified enzyme with the 
ability to discriminately degrade Sec, Scly is likely a key player in this pathway. When Scly is 
deleted, in order to maintain Sec below the threshold for toxicity, Sec decomposition likely 
occurs through an alternate pathway. Interestingly, enzymes of the sulfur metabolic pathways 
cannot distinguish between sulfur and its Se analogs, and as a consequence, Se compounds 
are indiscriminately metabolized through sulfur pathways123, although the regulatory factors that 
allow Se metabolism through sulfur pathways are unclear. An important role for Cys lies in its 
ability to be utilized in glutathione synthesis through the actions of enzymes glutamate cysteine 
ligase and glutathione synthase (GS). One possibility is that Sec is used to synthesize seleno-
glutathione via the glutathione synthesis pathway. Another possibility is that Sec is degraded 
through cysteine degradation mechanisms. Cysteine desulfurases such as Nfs1 remove the 
sulfur atom from cysteine, and unlike Scly, can indiscriminately degrade Sec and Cys. In fact, a 
study in Trypanosoma brucei found that the cysteine desulfurase activity containing Nfs protein 
is able to compensate for the loss of Scly124.  
 
 Potential alterations in the cysteine pathway in response to Scly deletion is particularly 
intriguing in light of surmounting evidence that an increase in total plasma Cys levels are 
strongly correlated with increased fat mass, and likely has a causative effect125,126. In terms of 
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islet function, Cys and its biologically active metabolite hydrogen sulfide (H2S) consistently 
inhibit GSIS in both insulin secreting cell lines and isolated pancreatic islets127–129. Recently, it 
was found that the Cys-dependent reduction of GSIS is due to the direct inhibitory effects of Cys 
on the activity of pyruvate kinase muscle isoform 2, resulting in a decreased flux of metabolites 
through the tricarboxylic acid cycle129. Moreover, H2S was found to directly inhibit L-type Ca2+ 
channels that are necessary for insulin vesicle release128. Improved understanding of the 
influence of Scly deletion on glutathione synthesis enzymes and cysteine degradation pathways 
will provide insight to the fate of Sec and insights to its downstream effects on insulin secretion. 
Although we failed to establish significance in mRNA expression of sulfur pathway enzymes 
(Figure 6), it is nevertheless interesting that an increase in fold change in comparing WT vs. 
Scly-/- islets was observed in each gene that was measured. Moreover, mRNA expression does 
not always correlate with protein or activity levels. Thus, the possibility that sulfur pathways 
compensate for the absence of Scly should not be precluded. 
 
 Several amino acids act as nutrient signals that can potentiate insulin secretion130. Of 
particular interest, acute alanine stimulation was found to have an insulinotropic effect131. It is 
possible that the alanine produced as a byproduct of Sec decomposition may influence islet 
function. However, the pool of Sec in relation to other amino acids is small. Thus, the 
contribution of alanine generated by Sec in insulin secretion is likely minimal. 
 
 Our findings elucidate a role for Scly in maintaining pancreatic islet function in a 
selenoprotein-independent manner. While it is possible that loss of Scly results in alterations in 
sulfur pathways, further investigation is necessary to determine the metabolites that are 
affected. 
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CHAPTER 3. SEX DIFFERENCES IN SELENOCYSTEINE LYASE REGULATION OF 
ENERGY METABOLISM 
3.1 Introduction 
 In the past, female research subjects have been largely been excluded from biomedical 
research. It was not until 1993 that the National Institutes of Health (NIH) mandated the 
inclusion of women in NIH-funded research132. Since then, many sex differences in disease 
pathogenesis have been reported. Relevant to the current study is the increased understanding 
of the sex-specific pathophysiology of type 2 diabetes133. For instance, adipocytes of women are 
more insulin sensitive than men133. One study in mice suggested that this effect could be due to 
positive effects of estrogen on GLUT1, GLUT4, fatty acid synthase (FAS), and acetyl-CoA 
carboxylase (ACC), key components of glucose and lipid metabolism134. On the other hand, 
women are at a higher risk of death due to T2D-related cardiovascular issues135. Enhancing 
prevention and treatment strategies for T2D and other diseases would greatly benefit from 
elucidating mechanistic differences in T2D pathophysiology in males and females.  
 
 Sex differences in Se regulation are well documented, but not well understood. In 
particular, Se appears to be critical to the male reproductive system. Although Se can be found 
in many tissues, a significant portion of dietary Se is routed to the male reproductive system, 
and under times of Se deprivation Se uptake is prioritized to the brain and testes136. When the 
Se transport selenoprotein SELENOP is knocked out in mice, the males become infertile while 
female mice maintain fertility137. To further support the sexual dimorphism in Se regulation, male 
SELENOP-/- mice develop neurological dysfunction to a greater extent than their female 
counterparts. Because of the Se salvaging capability of Scly and the presence of multiple Sec 
residues in SELENOP, it has been suggested that their concerted action is necessary for Se 
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transport and delivery to tissues117. Even under Se supplementation, male Scly-/-SELENOP-/- 
mice develop audiogenic seizures and have reduced survival, producing a far worse phenotype 
than the deletion of either one of these genes35. Strikingly, castration is sufficient to rescue Scly-
/-SELENOP-/- mice, suggesting that the testes competes for Se at the expense of neurological 
function, further reinforcing the importance of Se to male reproduction.  
 
 The hypothalamus is the master regulator of energy homeostasis, sensing nutrient 
availability and subsequently fine-tuning energy intake and expenditure through its downstream 
targets138. Impairment of selenoprotein synthesis through the deletion of Sec-tRNA[Ser]Sec from 
the hypothalamus resulted in severe glucose intolerance and insulin resistance in mice139, 
indicating that hypothalamic selenoprotein function is necessary to maintain energy metabolism. 
Nevertheless, we do not know whether Scly is involved in hypothalamic selenoprotein 
biosynthesis.  
 
 Although the association between higher incidence of T2D and elevated Se levels in 
humans is controversial, it is nevertheless interesting that this association appears to be 
restricted to men140. We previously reported that female Scly-/- mice have a less pronounced 
metabolic phenotype than their male counterparts38, suggesting that sex differences in the 
regulation of Se metabolism may have direct consequences on energy metabolism. In the 
present study, we hypothesized that the Se demands of the male reproductive system have a 
detrimental effect on energy metabolism in male Scly-/- mice. We first characterized the 
metabolic phenotype of female Scly-/- mice. Next, we tested the effects of castration of male 
mice on body weight, energy expenditure, and measures of insulin secretion and resistance.   
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3.2 Methods 
3.2.1 Animals 
 Protocols are as described in Chapter 2. 
 
3.2.2 Castration and Testosterone (TST) replacement 
 Five-week-old male mice were anesthetized with isofluorane (2 liters/min) and a 1-2 cm 
ventral midline incision was made in the scrotum to expose the tunica. The tunica was pierced 
and the testes pushed out one at a time and excised while all deferential vessels and ducts 
were replaced. A 0.75 cm incision was made in the neck where either a 60-day controlled 
release placebo or 1 mg TST pellet (Innovative Research of America, Sarasota, FL) was 
inserted. For long-term studies, a second pellet was inserted after 60 days. Skin incisions were 
closed with 6.0 surgical silk. Animals were given ibuprofen and allowed to recover for one week. 
Sham operations were also performed as a control. Serum TST levels were confirmed using a 
TST ELISA kit (Crystal Chem, Downers Grove, IL) according to manufacturer’s instructions. 
 
3.2.3 Measurement of metabolic parameters 
 For glucose tolerance test (GTT), mice were fasted overnight and injected 
intraperitoneally with glucose (1 g/kg of body weight). Tail vein blood was collected at 0, 30, 60, 
120 min post-injection and tested for glucose with a glucometer (LifeScan, Milpitas, CA). For 
fasting insulin, tail blood was collected after a 4-hour fast. Serum insulin was measured using a 
mouse ultrasensitive insulin ELISA (ALPCO, Salem, NH).  
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3.2.4 Measurement of energy expenditure 
 Mice were habituated in the metabolic cages overnight, one week prior to metabolic 
testing, in order to reduce stress levels which can affect oxygen consumption. Food intake, 
activity, volume oxygen consumption (VO2), and volume carbon dioxide (VCO2) measurements 
were obtained over a 24-hour period using the Panlab OxyletPro™ System (Barcelona, Spain). 
VO2 measurements were used to calculate the respiratory quotient (RQ), from which preferred 
substrate utilization was estimated using the Lusk equation. The Lusk equation allows us to 
calculate fat and carbohydrate oxidation from VO2 consumed and heat produced141. Data were 
analyzed using the Panlab METABOLISM software.  
 
3.2.5 Immunohistochemistry and islet size determination 
 Mice were anesthetized with Avertin and perfused with 4% paraformaldehyde. 
Pancreases were excised, embedded in paraffin, and sectioned at 5 μm thickness using a 
microtome (Leica; Wetzlar, Germany). Sections were antigen retrieved by boiling in citrate 
buffer, as described in chapter 2.  M.O.M. basic kit (Vector Labs, Burlingame, CA) was used to 
stain for insulin according to manufacturer’s instructions. Endogenous peroxide activity was 
blocked using 3% H2O2 in water for 5 minutes. Vectastain Elite ABC kit (Vector Labs) and DAB 
substrate kit (Vector Labs) were used for detection according to manufacturer’s instructions. 
Hematoxylin was used as a counterstain to visualize nuclei. Anti-insulin was purchased from 
Millipore (Billerica, MA). To determine average islet size, images were taken using the 10x 
objective. Islet size was measured for 6-8 islets per mouse using ImageJ software. 
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3.2.6 Western Blot 
 Mouse whole brain was removed and incubated in ice-cold 0.32 M sucrose solution for 5 
min before placing in a mouse brain matrix with 1-mm slice intervals, ventral side facing up. 
Using a razor blade, a 2-mm slice was cut starting at the optic chiasm. The section was placed 
on a filter paper and the hypothalamus was extracted using a scalpel under a dissecting scope. 
Tissues were re-suspended in Sigma CelLytic™ MT (St. Louis, MO) with 1% Protease Inhibitor 
Cocktail III (Calbiochem; San Diego, CA) and disrupted with a sonicator using 3X 10 second 
pulses over ice. Protein concentration, SDS-PAGE, and Western Blot were performed as 
described in Chapter 2.  
 
3.2.7 Statistical analyses 
 For castration studies, Dunnett’s multiple comparison was used to compare all groups to 
WT control following ANOVA. All other statistical analyses were performed as described in 
Chapter 2. 
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3.3 Results 
3.3.1 Female Scly-/- mice have increased adiposity but fasting insulin and glucose tolerance 
remains intact 
 It was previously reported that male Scly-/- mice develop a metabolic syndrome-like 
phenotype that is exacerbated when Se supply is limited38. Female Scly-/- mice were not 
included in the initial study because their phenotype appeared to be milder. In the present study, 
we fed a low Se diet to female WT and Scly-/- mice and tested the effects of Se deficiency on 
their metabolic phenotype. At 8 weeks of age, the body weights of female Scly-/- mice were not 
distinct from their WT counter parts. A time course assessment of body weight revealed a main 
effect of genotype, time, and interaction. Post hoc analysis showed that by 12 weeks of age, 
female Scly-/- mice were significantly heavier than their WT counterparts, a trend that persisted 
at least up to 20 weeks of age (Figure 7A,B). This time point was chosen because symptoms of 
metabolic syndrome in male Scly-/- begin to appear by 20 weeks of age. Female Scly-/- also had 
a significantly higher percentage of gonadal fat deposition (Figure 7C). We administered an 
intravenous glucose tolerance test, but found no differences in glucose clearance (Figure 7D,E), 
further confirming female Scly-/- are insulin sensitive. In contrast to what was previously 
observed in male Scly-/- mice38, fasting insulin levels were similar between both genotypes in 
female mice (Figure 7F). Taken together, our results demonstrate that similar to their male 
counterparts, a low Se diet in female Scly-/- mice results in increased adiposity, but unlike male 
mice, female Scly-/- mice do not develop hyperinsulinemia or reduced glucose tolerance. 
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For metabolic characterization, WT: n=4, Scly-/-: n=7. Unless otherwise indicated, mice 
were 22-weeks-old. (A) Mean body weight of female WT and Scly-/- mice at the indicated 
time points (Two-way ANOVA: time F3,27=99.33 p<0.0001, genotype F1,27=25.38 
p=0.0007, interaction F3,27=13.87 p<0.0001), (B) body weight displayed as % change 
(Two-way ANOVA: time F3,27=83.62 p<0.0001, genotype F1,27=19.88 p=0.0016, interaction 
F3,27=9.60 p=0.0002), (C) mean % gWAT, (D) mean glucose tolerance test in 20-week-old 
mice, (E) glucose tolerance area under the curve (AUC), (F) mean fasting serum insulin. 
All data are represented as means ± S.E.M. 
Figure 7. Metabolic characterization of female Scly-/- mice on a Se deficient diet. 
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3.3.2 Castration does not rescue the metabolic phenotype of male Scly-/- mice, but restores 
fasting insulin levels, while testosterone replacement had no effect 
 To determine whether the male reproductive system accounts for the adverse effects on 
energy metabolism in male Scly-/- mice, we investigated the effects of castration in a long-term 
study. Scly-/- mice were castrated at 5-weeks-old and were monitored for 4 months. This time 
point was chosen because we previously reported that Scly-/- mice on a Se adequate diet 
become significantly obese at this age38. If castration rescues energy metabolism dysfunction in 
Scly-/- mice, there are two possible explanations. The first of these is that removal of the testes 
results in a diminished demand of Se for reproduction. However, since testes are the main site 
of TST production, castration results in low TST levels. Thus, to test this possible effect TST, we 
set up 4 experimental groups consisting of WT sham-operated, Scly-/- sham-operated, Scly-/- 
Figure 8. TST dose-response curve to determine the appropriate dose for TST. 
replacement experiments. 5-week-old mice were castrated and implanted with the indicated dose of TST pellet. Serum 
TST was measured one month after implantation. Implantation with 1 mg pellet restored TST 
to WT levels. For WT sham n=6, for castrated groups n=2-3. All data are represented as 
means ± S.E.M. 
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castrated+placebo, and Scly-/- castrated+TST replacement. A dose response curve was used to 
determine the appropriate TST dose (Figure 8). The 1 mg dose was chosen because it restored 
TST levels to similar levels as WT mice.  
 
 In our first cohort of mice, we observed that in TST implanted mice, hair growth was not 
restored at the site of TST implantation for the full length of study. In our second cohort, we 
observed hair growth and less aggressive behavior approximately 30 days after TST 
implantation, prompting us to test our pellets. We suspected we were sent 30-day release 
tablets rather than 60-day tablets. Our results show that 15 days after implantation, serum TST 
levels were approximately 5-6 ng/ml (Table 3). At 30 days, TST levels are halved. By 45 days 
after implantation, TST levels were indistinguishable from castrated mice. These data are 
summarized in Table 3. Thus, we proceeded with our study with the following groups: WT sham, 
Scly-/- sham, and Scly-/- castrated.  
 
 
 
 
Table 3. TST levels drop to castrated levels 45 days after pellet insertion.                                       Serum 
TST (ng/ml) levels at the indicated days post-implantation of TST pellet. Values 
represent serum TST for a single animal, and values in the third column represent 
biological replicates. 
 
 Castrated+placebo Castrated+1 mg TST 
15 days 0.005 5.226 6.177 
30 days 0.024 3.342 3.092 
45 days 0.038 1.469 0.069 
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 Six weeks post-surgery, Scly-/- sham-operated mice were heavier than WT sham-
operated mice, whereas Scly-/- castrated mice weighed less than WT sham-operated mice. This 
trend continued at 10 weeks, persisting until at least 15 weeks after surgery (Figure 9A). We 
predicted that if testes played an adverse effect, body weights of castrated mice would be 
restored to WT. Bonferroni’s post-test following ANOVA revealed that castrated Scly-/- mice 
indeed weighed less than their sham operated counterparts at 10 weeks (p<0.001) and 15 
weeks (p<0.001) post-surgery. However, castrated mice weighed significantly less than WT 
mice at both 10 weeks (p<0.05) and 15 weeks (p<0.05) post-surgery. Despite the differences in 
body weight, both sham-operated and castrated Scly-/- mice had significantly higher inguinal 
white adipose tissue (WAT) composition when compared to WT sham mice using Dunnett’s 
multiple comparison (Figure 9B). Additionally, food intake was lower than WT in Scly-/- sham 
mice and Scly-/- castrated mice (Figure 9C).  
 
 Indirect calorimetry revealed significant differences in VO2 when comparing WT to Scly-/- 
sham and a similar trend when comparing WT to castrated mice, although values did not reach 
significance (Figure 9D,E). Both groups of Scly-/- mice had decreased energy expenditure 
(Figure 9F,G) and RQ (Figure 9H,I) when compared to WT. WT sham mice preferentially 
burned carbohydrates compared to Scly-/- sham and castrated mice (Table 4).  
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Figure 9. Bodyweight, adiposity, food intake, and energy expenditure in response to 
castration. 
 
         Unless indicated, all metabolic parameters were measured in 5-month-old mice. 
For WT sham-operated mice: n=6, Scly-/- sham-operated mice: n=8, Scly-/- castrated mice: 
n=6. (A) Mean body weight at the indicated time points after surgery. One-way ANOVA was 
used to test each time point (6 weeks: F2,17=5.88, p=0.01; 10 weeks: F2,17=14.0, p=0.0003; 15 
weeks: F2,17=18.66, p<0.0001) and Dunnett’s post-test was used to compare all groups to 
WT (WT vs. sham: ^p<0.05, WT vs. castrated: *p<0.05), (B) mean iWAT depots displayed as 
% of bodyweight (One-way ANOVA: F2,17=5.94, p=0.01), (C) food intake over 24 hours (One-
way ANOVA: F2,15=7.29, p=0.006), (D) VO2 profile over 24 hours. One measurement was 
taken every hour, and each point represents an average of n=6 for WT and castrated mice, 
and n=8 for sham-operated mice. The black bar corresponds to measurements taken during 
the dark cycle. (E) Area under the curve for VO2 (One-way ANOVA: F2,14=3.48, p=0.06) (F) 
energy expenditure over 24 hours, (G) area under the curve for energy expenditure (One-
way ANOVA: F2,14=5.76, p=0.01), (H) RQ over 24 hours, (I) area under the curve for RQ 
(One-way ANOVA: F2,14=8.81, p=0.003). For all measurements taken using metabolic cages, 
Dunnett’s post-test was used to compare all columns to WT (*p<0.05, **p<0.01, ***p<0.001). 
All data are represented as means ± S.E.M. 
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 In contrast to previous studies showing differences in glucose tolerance between WT 
and Scly-/-mice on an adequate Se diet38, no differences were observed in this study in glucose 
tolerance between Scly-/- and WT mice (Figure 10A,B). Nevertheless, fasting serum insulin 
levels were significantly different among the groups (Figure 10C). Interestingly, Bonferroni’s 
multiple comparison for all conditions revealed significant differences between Scly-/- castrated 
and   Scly-/- sham-operated mice.  
 
 To better understand the discrepancies in GTT with previous studies, we measured 
fasting serum insulin levels over time, comparing Scly-/- to WT mice. This time course study 
revealed a decrease in serum insulin levels in WT mice between 8 weeks and 12 weeks of age 
whereas fasting serum insulin levels in Scly-/- mice remains relatively unchanged. This caused 
significant differences in fasting insulin between WT and Scly-/- mice at 12 weeks of age 
(p<0.05), which persists at 16 weeks of age (p<0.001) (Figure 11). However, these differences 
are abolished by week 20 due to an increase in fasting serum insulin levels in WT mice. Thus, 
the similar rate of glucose tolerance between WT sham-operated and Scly-/- mice may partially 
be accounted for by their fasting serum insulin levels. 
 
 
Group RQ (average±S.E.M.) Carbohydrate % Fat % 
WT sham 0.98±0.04 93.2 6.83 
Scly-/- sham 0.93±0.04* 76.1 23.9 
Scly-/- castrated 0.89±0.01** 62.5 37.5 
 Table 4. Preferred substrate utilization of WT sham-operated vs. Scly-/- sham-operated 
and castrated mice.            Respiratory quotient values, % carbohydrate and fat burned over 24 h. 
(1-WA: F2,15=10.25, p=0.0016, Dunnett’s post-test comparing all columns to WT: *p<0.05, 
**p<0.01). 
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                    All parameters 
were measured using 5-month-old mice. For WT sham mice: n=6, Scly-/- sham mice: n=8, 
Scly-/- castrated mice: n=6.  (A) GTT, (B) GTT AUC, (C) serum insulin levels after a 4 hour 
fast (One-way ANOVA: F2,17=5.14, p=0.01).  
Figure 10. Effects of castration on parameters of insulin resistance.
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3.3.3 Effects of Castration on islet morphology 
 Next, we used immunohistochemistry to stain for insulin-positive cells in order to analyze 
islet morphology. Scly-/- castrated mice appeared to have smaller islets than WT sham and Scly-
/- sham-operated mice (Figure 12 & Figure 13). Islets from castrated Scly-/- mice also appeared 
to have acinar cell infiltration, which is indicative of β-cell failure142. Thus, the decrease in fasting 
serum insulin was likely due to a reduction in islet mass and density. 
 
 
  
                 Insulin 
secretion after a 4 hour fast at the indicated time points. Using repeated measures two-way 
ANOVA, there was a main effect for time (F4,28=18.45, p<0.0001), genotype (F1,28=16.03, 
p=0.0052), and interaction (F4,28=6.51 p=0.0008). Bonferroni’s correction revealed significant 
differences at 12, 16, and 24 weeks (*p<0.05, **p<0.01, ***p<0.001). For WT: n=4, KO: n=6. 
All data are represented as means ± S.E.M.  
Figure 11. Time course of fasting insulin secretion in male WT vs. Scly-/-.
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Figure 12. Pancreatic islets are smaller in Scly-/- castrated than Scly-/- sham-operated or 
WT sham-operated mice.            Pancreatic sections from 5-month-old WT sham, Scly
-/- sham, and 
Scly-/- castrated mice were labeled with anti-insulin and detected with DAB. Scale bar 
represents 50 μm. Images are representative of n=1-2. 
56 
 
3.3.4 Hypothalamic selenoprotein expression decreases in both male and female Scly-/- mice, 
even under Se adequate conditions 
 Recently, it was reported that loss of selenoproteins in the hypothalamus through a 
conditional knockout of Sec-tRNA[Ser]Sec resulted in T2D in mice139. Thus, we measured 
selenoprotein levels via Western Blotting in the hypothalamus of male and female Scly-/- mice 
under Se adequate conditions. In males, Scly-/- GPX1 levels were reduced to 29%±0.03 of the 
levels found in WT hypothalamus, SELENOM was reduced to 46%±0.05, and SELENOS was 
reduced to 71%±0.18 (Error! Reference source not found.A). In female mice, GPX1 
expression was at 44%±0.04, SELENOM levels at 24%±0.07, and SELENOS at 72%±0.07 of 
WT hypothalamus levels. On the other hand, expression of housekeeping selenoproteins 
SEPHS2 and TXNRD1 were unchanged (Error! Reference source not found.B). 
 
  
            Islet size was 
measured and averaged for 6-8 islets per mouse, n=1-2. 
Figure 13. Quantification of mean islet area in response to castration.
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Figure 14. Hypothalamic selenoprotein expression in WT vs. Scly-/- mice.                        
(A) Hypothalamic selenoprotein expression in male WT vs. male Scly-/- mice, n=6 and (B) 
female WT vs. female Scly-/- mice, n=5. Β-actin was used as a loading control. WT protein 
expression was normalized to 1. Unpaired, two-tailed t-test was used to compare WT vs.   
Scly-/- for each protein (*p<0.05, **p<0.01, ***p<0.001). All data are represented as means 
± S.E.M.  
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3.4 Discussion 
 Sex differences in Se and incidence of T2D in humans have been previously noted in a 
number of studies in which increased Se intake was correlated with susceptibility to T2D in men 
but not women104. However, the mechanism behind the sex differences in the relationship 
between Se and energy metabolism is unclear. We previously observed that female Scly-/- mice 
do not develop a metabolic phenotype to the same extent as their male counterparts. Thus, we 
wondered whether the sexually dimorphic outcome of Se in T2D could be attributed to sex-
specific regulation of Scly. In order to answer this question, we first characterized female mice. 
Our results revealed that in accordance with our previous observations, unlike their male 
counterparts, female Scly-/- mice have normal glucose tolerance, insulin signaling, and fasting 
insulin levels (Figure 7D-G). To our surprise, female Scly-/- mice developed higher body fat 
composition than WT mice (Figure 7C). The protective effects of estrogen against insulin 
resistance have been well documented143. For instance, pre-menopausal women are protected 
from the impacts of a high fat diet on insulin resistance when compared to age-matched men, 
but these effects are abolished in menopausal women144. Additionally, estrogen replacement 
has been shown to directly improve insulin sensitivity145. Thus, we suspect that the presence of 
estrogen may have masked the effects of increased adiposity on insulin resistance in female 
Scly-/- mice.  
 
 Scly was previously found to be expressed in spermatocytes and the Leydig cells of the 
testes117. In addition, castration of Scly-/-SELENOP-/- mice attenuated their severe neurological 
phenotype, suggesting Se distribution to the testes is prioritized146. Together, these results 
reinforce the importance of Se delivery and recycling to testes function and male fertility. Thus, 
the possibility that the Se demands of the testes produces adverse effects on the function of  
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metabolic tissues in Scly-/- mice could not be excluded. We therefore castrated Scly-/- mice to 
evaluate whether testes removal could rescue the metabolic dysfunction in Scly-/- mice. Without 
the testes, perhaps circulating Se would be more readily available for distribution to metabolic 
tissues. An unanticipated result of the castration was that the body weights of castrated Scly-/- 
mice were lower than WT mice (Figure 9A). TST deficiency in men leads to loss of lean body 
mass147, and a similar phenomenon in mice may have been a confounding factor in our studies.  
 
 Body fat composition was higher in Scly-/- mice than in WT, and indistinguishable 
between sham-operated and castrated Scly-/- mice, despite the lower body weight of the 
castrated mice (Figure 9B). Interestingly, food intake was lower in both Scly-/- groups compared 
to WT mice (Figure 9C). As an adipokine, leptin levels rise with increasing fat accumulation, 
regulating hunger in response to fat stores. We previously reported that Scly-/- mice indeed have 
increased circulating leptin38, and thus we speculate that the decreased food intake is a direct 
result of increased leptin in Scly-/- mice.  
 
 To our surprise, we did not observe changes in GTT between WT sham-operated and 
Scly-/- sham-operated mice (Figure 10A,B), as previously reported38. One disadvantage of the 
GTT test at a single time point is that we are only able to obtain a snapshot of glucose 
tolerance. As age is a known causative factor in obesity and insulin resistance development148, 
it is reasonable to consider that by 20 weeks of age, WT mice develop age-dependent insulin 
resistance. To address this, we conducted a time course study, revealing that at 20 weeks of 
age, fasting serum insulin in WT and Scly-/- mice are not significantly different (Figure 11). 
Although the insulin levels may suggest similar levels of insulin resistance between WT and 
Scly-/- sham mice, insulin resistance can only be confirmed using glucose clamps. Nevertheless, 
the insulin levels at 20-weeks-old may partially account for the lack of difference observed in 
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GTT. One interesting finding was that although male WT and Scly-/- mice had similar fasting 
insulin levels at 8-weeks-old, there was an inexplicable drop in serum fasting insulin levels at 
12-weeks-old in WT mice while Scly-/- insulin levels were maintained (Figure 11). This raises the 
question of whether Scly-/- mice develop hyperinsulinemia or fail to experience a drop in insulin 
levels. Further investigation is necessary to determine whether a significant decrease in fasting 
insulin levels after 8 weeks of age is a typical event in WT mice.   
 
 We found castration to significantly reduce fasting serum insulin levels (Figure 10C). 
Assessment of islet morphology revealed islets from Scly-/- castrated mice to be smaller than 
from Scly-/- sham-operated and WT sham-operated mice (Figure 12 & Figure 13). The smaller β-
cell mass in Scly-/- castrated mice likely accounts for the lower fasting serum insulin levels, 
which may be the outcome of either of two possible explanations. On one hand, it is possible 
that castration rescued insulin sensitivity and β-cell function, eliminating the need for 
hyperplasia as a compensatory mechanism, resulting in what appears to be smaller β-cell mass. 
If this were the case, we would likely see improved body fat composition, energy expenditure, 
glucose tolerance, and fasting blood glucose levels, in Scly-/- castrated mice; however, none of 
these were observed. Thus, it is more likely that altered insulin secretion in castrated Scly-/- mice 
is due to β-cell decompensation, which is characterized by a reduction of β-cell mass149.  
If this is the case, we should see a reduction in markers of β-cell identity such as Pdx1 and 
musculoaponeurotic fibrosarcoma oncogene family A (MafA). Androgen deficiency in men has 
been known to have detrimental effects on obesity and insulin sensitivity150. More recently, it 
was found that TST has direct effects in maintaining β-cell function in male mice151. Hence, Scly-
/- castrated mice are likely experiencing a poorer outcome in terms of β-cell health as a 
consequence of TST deficiency. 
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 Our finding that body fat composition is higher than WT in Scly-/- mice regardless of sex 
(Figure 7C & Figure 9B), points to a likely involvement of Scly in lipogenesis and/or lipolysis. 
However, we previously reported Scly was expressed minimally in the WAT when compared to 
the liver, while another study which measured Scly activity in rat tissues failed to detect Scly 
activity in the WAT31,38, indicating that the regulatory action of fat stores through Scly is likely 
indirect. We demonstrate that even on a Se adequate diet, expression of selenoproteins was 
diminished in the hypothalamus when Scly-/- was absent (Figure 14). This is in contrast to a 
previous study from our laboratory which found selenoprotein mRNA from whole brain to be 
unchanged in Scly-/- mice152, suggesting that Scly may play a more prominent role in 
selenoprotein biosynthesis in certain brain regions than others.  
 
 Crosstalk between the hypothalamus and WAT is well documented, and mostly 
attributed to the adipokine leptin153. Recently, it was found that direct sympathetic efferent 
contact with the WAT is critical to the action of leptin on lipolysis via the hypothalamus154. Thus, 
it is tempting to speculate that Scly influences WAT function by regulating selenoprotein 
expression in the hypothalamus. In support of this, a recent study found that deletion of Sec-
tRNA[Ser]Sec from the hypothalamus results in increased adiposity and insulin resistance139. The 
effects were found to be a direct result of increased oxidative stress due to the absence of Sec-
tRNA[Ser]Sec.  
 
 We previously showed that SELENOM knockout mice develop obesity and decreased 
leptin signaling79. Interestingly, SELENOM was one of the selenoproteins which we found to be 
downregulated in the hypothalamus of Scly-/- mice. The reduction in hypothalamic selenoprotein 
expression was observed at 10-weeks-old of age, prior to significant changes in energy 
metabolism. Thus, diminished selenoprotein expression is likely a contributing factor to 
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alterations in energy metabolism, rather than a consequence. This invites speculation that Scly 
may protect against alterations in lipid metabolism, through the regulation of select 
selenoproteins. 
 
 Taken together, our results suggest a novel role for Scly in regulating energy metabolism 
through the hypothalamus. Scly appears to be critical for efficient hypothalamic selenoprotein 
biosynthesis, particularly for the Se-responsive selenoproteins. An interesting avenue for further 
investigation would be to determine whether hypothalamic Scly protects against high fat diet 
and whole-body insulin resistance.  
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CHAPTER 4. CONCLUSION 
4.1 Final Remarks 
 Until the generation of Scly-/- mice, much of the pioneering work involving Scly function 
was accomplished through in vitro methods31. Scly is known to be involved in selenoprotein 
biosynthesis and Se recycling117, but its physiological role has only recently begun to be 
appreciated. It is proposed that Scly coordinates with SELENOP to supply Se to tissues such as 
the brain and testes117. Yet, we found that in contrast with SELENOP-/- mice, Scly-/- mice fail to 
develop a neurological phenotype, nor do they exhibit impairments in fertility152. Under a Se 
deficient diet, Scly-/- mice develop mild deficits in spatial learning accompanied by a reduction in 
brain GPX activity as well as GPX1 and GPX4 expression, indicating a role for Scly in regulating 
brain selenoprotein expression when exogenous Se supply is low, and it is likely due to its Se 
recycling ability. In a follow up study, we found that Scly-/- mice develop a metabolic syndrome-
like phenotype in a sex-dependent fashion, uncovering a relationship between Scly and 
pathways involving energy metabolism38. 
 
 The current project advances our understanding of Scly in energy metabolism. One of 
the most striking features of the Scly-/- mice, which paved the way for the current project, is its 
development of severe hyperinsulinemia38. This is particularly interesting to us because of 
previous reports which suggest that selenoproteins are critical in regulating pancreatic islet 
function60,86,111. Therefore, we pursued the investigation of Scly function in the pancreatic islet. 
While changes were not observed in GSIS, our results are nonetheless exciting, as to the best 
of our knowledge, they were the first to describe Scly expression in the pancreatic islet. 
Because we did not find islet selenoprotein expression to be influenced by Scly on a Se 
sufficient diet, we considered the possibility that Scly may be regulating insulin secretion and/or 
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islet function in an enzyme-activity independent manner. For instance, the ability of sulfur 
pathways to compensate for Sec accumulation may influence insulin secretion as an off-target 
effect. Our characterization of female mice revealed that female Scly-/- mice also develop higher 
body fat composition, but were likely protected from insulin resistance due to the presence of 
estrogen. Impaired hypothalamic selenoprotein biosynthesis in both male and female Scly-/- 
mice paves the way for a previously unexplored role for Scly in the brain-fat axis. 
 
 Finally, an important topic for discussion is the translational relevance of Scly-/- mice to 
human studies. Presently, literature citing Scly in human metabolic diseases is scarce, with only 
one study identifying an association between human Scly polymorphisms and alterations in lipid 
pathways41. Nevertheless, further investigation of Scly in T2D and metabolic syndrome should 
be pursued to better understand human health. An interesting consideration is the relationship 
between supra-nutritional Se intake, Scly, and T2D. Human clinical trials have uncovered a 
positive correlation between Se intake and increased incidence of T2D when baseline Se levels 
are already at the upper tolerable limit51. Given that Scly is inversely regulated by increasing Se 
levels in vitro (Figure 4A), it is conceivable that human Scly activity may also be impacted by 
fluctuating serum Se concentrations. As modern technology has improved food import and 
export, human health concerns due to Se deficiency have mostly been eradicated. Despite 
receiving an adequate supply, at least 18-19% of adults reported taking Se supplements155. The 
potential threat of T2D with supra-nutritional Se intake is alarming, and further understanding of 
Se metabolism is necessary in preventing unwanted effects on energy metabolism. 
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4.2 Future Directions 
 
 An intriguing finding in our immunofluorescence images of pancreatic islets was an 
apparent association of Scly with the nucleus in contrast to it being found solely in the cytosolic 
fraction when nuclear and cytosolic fractions were separated. As the majority of Scly substrates 
are in the cytosol, a predominant cytosolic localization would have been expected. However, as 
other components of selenoprotein biosynthesis have been found to participate in 
nucleocytoplasmic shuttling119,156, it is possible that Scly is also involved in this process. Scly is 
not known to contain a nuclear localization or nuclear export signal117, and therefore nuclear 
import would likely involve association with a transport protein. Alternatively, Scly is associated 
with the cytoplasmic side of the nuclear membrane. Future studies will attempt high-resolution 
separation of immunostaining within the nucleus as opposed to the nuclear membrane. If 
targeted to the nuclei, future experiments could focus on the identification of potential interactor 
protein(s) that allows Scly to enter the nucleus. In the context of metabolic diseases, it would be 
valuable to determine if conditions such as glucotoxicity or lipotoxicity influence the subcellular 
localization of Scly. 
 
 While selenoprotein biosynthesis is well-studied, much less is known about Sec 
degradation. Scly is unique in that it has evolved to specifically accept Sec as a substrate in 
vertebrates, despite the ability of sulfur pathway enzymes to participate in Se metabolism32. This 
raises speculation that efficient Sec decomposition is beneficial, but more in-depth studies 
involving Scly are necessary to fully understand the advantage of a system which recognizes 
Sec with such high specificity. While we assessed gene expression of sulfur pathway enzymes 
in the present study, measuring protein and activity levels would provide a more accurate 
representation of how the sulfur pathways are affected by Scly deletion and how they might 
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compensate to handle an expected increase in Sec level in the absence of Scly. 
 
 Thus far, the physiological function of Scly has been attributed to its ability to generate 
selenide. Nevertheless, we observe metabolic dysfunction in Scly-/- mice despite selenoprotein 
biosynthesis remaining intact in most tissues. An important consideration is that Scly regulation 
of energy metabolism may occur independent of its enzymatic activity. One way to test this 
would be to inactivate the Sec decomposing capacity of Scly by introducing a mutation in its 
active site. If Scly enzymatic activity is critical in its regulation of energy metabolism, we expect 
a similar outcome to Scly deletion. In contrast, if Scly enzymatic activity is negligible, mutation of 
the active site will likely not impact energy metabolism. 
 
 We have also provided insight to the potential role of Scly in regulating energy 
metabolism through the hypothalamus, suggesting Scly may regulate the brain-fat axis. 
Possibly, in the absence of Scly, inefficient selenoprotein biosynthesis in the hypothalamus 
drives WAT accumulation. One explanation is that decreased selenoprotein expression could 
lead to increased oxidative stress and/or neurodegeneration in the hypothalamus, leading to 
detrimental consequences in lipolysis and/or lipogenesis in the periphery. Conditional knockout 
studies involving Scly deletion from the hypothalamus would clarify the role of Scly in the brain-
fat axis. Moreover, it would be interesting to restore Scly expression in the hypothalamus to 
determine if WAT lipogenic/lipolytic pathways are rescued, which could be determined by 
measuring body fat composition and lipid pathway enzymes such as hormone sensitive lipase, 
ACC1, lipoprotein lipase, and peroxisome proliferator-activated receptor. Overall, these studies 
will begin to uncover a mechanistic role for Scly in the hypothalamic regulation of energy 
metabolism. 
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